Next-generation biomedical nanorobots: active design, intelligent control, and translational opportunities in regenerative and minimally invasive medicine Authors: Na Liu, Shi Tang, Shasha Yu, Yang Song, Haishan Zhang, Yizi Wang Published: 2026 ABSTRACT AbstractBiomedical nanorobots represent an emerging class of active nanosystems that enable controlled navigation, sensing, and targeted intervention within complex biological environments. This review presents recent developments in nanorobot design, highlighting key material architectures, including inorganic, soft, hybrid, and biohybrid systems and their modular integration for biomedical functionality. Major propulsion and control strategies, such as chemical, magnetic, and acoustic actuation, are discussed alongside emerging capabilities in environmental sensing, swarm intelligence, and AI-assisted control. Applications in regenerative medicine and MIIs are examined, with emphasis on targeted drug delivery, tissue repair, and theranostic systems across diverse disease contexts. Despite promising preclinical progress, significant translational challenges remain, including biological interactions, long-term biosafety, manufacturing scalability, and regulatory uncertainty. Finally, we outline key research priorities, including the development of biodegradable systems, standardized evaluation frameworks, and integration with imaging and digital medicine, to facilitate the safe and effective clinical translation of nanorobotics.Graphical Abstract Keywords: Nanorobotics, Regenerative medicine, Minimally invasive interventions, Biomedical nanotechnology, Targeted drug delivery, Biohybrid nanorobots Introduction Background and evolution of nanorobotics in biomedicine Nanotechnology has played a remarkable role in contemporary biomedicine by enabling therapeutic and diagnostic manipulation at length scales relevant to biological molecules, subcellular structures, and cellular machinery. Conventional nanosystems (e.g., liposomes and polymeric nanoparticles) have achieved notable clinical success but remain fundamentally limited by passive transport and restricted spatiotemporal control [1]. Some of these platforms have been clinically translated and proven to have significant value in drug delivery and imaging. These limitations have motivated the development of active nanoscale systems capable of dynamic interaction with complex biological environments [2]. BSs are inherently dynamic, heterogeneous, and multiscale, composed of fluid flows, tissue barriers, immune surveillance, and a dynamically changing microenvironment [3]. Immobilized nanocarriers that rely on non-specific targeting rely on diffusion and are usually unable to respond to these conditions, resulting in heterogeneous distribution, limited tissue penetration, and reduced effectiveness. These limitations have driven the transition toward nanorobotics, a field focused on active nanoscale systems capable of controlled motion, sensing, and interaction with their environment [4, 5]. Biomedical nanorobotics represents a paradigm shift from passive delivery to active, adaptive, and programmable nanosystems. Advances in materials science, nanoscale fabrication, and biohybrid engineering have enabled the development of chemically powered nanomotors, magnetically actuated nanoswimmers, and biologically driven platforms [6, 7]. Chemical energy-powered nanomotors have been demonstrated to exhibit controlled movement, environmental responsiveness, and localized tasks, as well as magnetically driven nanoswimmers, acoustically driven systems, and biologically driven platforms. This represents a paradigm shift from passive delivery systems to active, adaptive, and even intelligent nanosystems, in which nanorobotics is a potential approach for precision, minimally invasive biomedical delivery [8, 9]. Distinction between nanorobots, nanoparticles, and microrobots A clear distinction between nanoparticles, nanorobots, and microrobots requires not only consideration of size and functionality but also of their interactions with physiological constraints and anatomical accessibility in biological environments. Traditional nanoparticles (typically 10–200 nm) are passive systems that rely on diffusion, vascular permeability, and ligand-mediated targeting [10]. While surface functionalization can improve targeting through the incorporation of targeting ligands or stimulus-responsive elements, these systems typically do not move autonomously, navigate actively, or make decisions. As a result, their penetration into dense tissues is often limited, leading to heterogeneous distribution and reduced therapeutic efficacy [10, 11]. The microrobots, however, will operate at larger length scales and can employ more advanced actuation, sensing, and control systems because there are fewer fabrication limitations. Microrobots have been shown to navigate and manipulate in tight anatomical spaces using magnetic or acoustic actuation, exploiting differences in their responses to these stimuli [12, 13]. They are, however, too large to be delivered systematically, are inaccessible to the microvasculature or dense tissue, and pose issues of invasiveness, clearance, and long-term safety [14]. Nanorobots conceptually bridge this gap, combining nanoscale accessibility with active functionality. They integrate propulsion, sensing, targeting, and control within nanoscale architectures, enabling interaction with confined biological environments such as capillaries and extracellular matrices. Nanorobots will solve significant shortcomings of both by incorporating propulsion, sensing, targeting, and control functionality into nanoscale structures. This distinction is particularly relevant to RM and minimally invasive surgery, where the need to reach closed biological cavities, navigate through them, cause minimal tissue damage, and act locally is required. This size-function-environment interplay provides a more mechanistic and application-relevant framework for distinguishing these platforms in biomedical applications [15, 16]. Clinical needs in RM and MIIs RM seeks to replace the shape and function of injured tissues and organs through processes that consume cells, biomaterials, and bioactive signaling molecules. Despite progress, key challenges persist, including homing to cells, engraftment defects, loss of growth factor control, immune-mediated rejection, and poor integration into host tissue, which have yet to be addressed. They are typically associated with ineffective therapeutic responses and impede clinical translation [17, 18]. Similarly, the least invasive medical procedures are designed to minimize patient trauma, recovery time, and the incidence of complications compared with conventional surgical procedures. While advances in imaging and catheter-based systems have improved outcomes, limitations remain in accessing complex anatomical regions and achieving cellular-level precision. These problems are the primary drivers of the need for technologies that provide high spatial resolution and dynamic responses to local biological conditions [15, 19]. Nanorobots can address unmet clinical needs by trafficking and delivering therapeutic agents precisely and by interacting in real time with the biological microenvironment. They are small, which enables them to enter narrow spaces, including capillaries, extracellular matrices, and tissue interfaces, and active control processes can localize and function them with great precision [20, 21]. Nanorobots offer a potential solution to these unmet clinical needs by enabling active navigation, localized delivery, and real-time interaction with biological microenvironments. They provide an opportunity to deliver medication accurately and locally and to access areas previously inaccessible through minimally invasive procedures. These attributes are highly clinically oriented and would allow biomedical nanorobotics to continue to be researched and developed [22, 23]. Scope of this review This review aims to provide a critical and integrative examination of biomedical nanorobotics, focusing on their application in regenerative medicine and MIIs. The paper integrates developments in materials science, engineering, biology, and clinical research to facilitate a discussion of the opportunities and limitations of NSs, rather than providing a strictly descriptive overview. Rather than providing a purely descriptive overview, this work adopts a systems-level perspective, linking material design, propulsion mechanisms, sensing capabilities, and biological performance with translational considerations [24, 25]. Importantly, this review examines design strategies and applications by integrating regenerative medicine and MIIs within a unified clinical framework, highlighting the interplay among engineering design, in vivo functionality, and translational feasibility. While recent reviews have summarized nanorobot design and applications [26, 27], this work provides a more integrative and critical perspective. Specifically, it addresses key challenges, including the trade-off between propulsion efficiency and controllability, the uncertain link between active motion and therapeutic efficacy in complex physiological environments, and ongoing issues in biosafety, immune interactions, long-term stability, scalability, and regulatory standardization, thereby guiding future clinically translatable NSs. Design principles and architectures of BNs Structural materials and fabrication strategies The structural design of BNs is based on the characteristics of the materials used to produce a particular shape and on the assembly process. This has clear magnetic, optical, catalytic, and imaging properties that underpin the extensive literature on inorganic nanomaterials, including gold, iron oxides, platinum, silica, and other systems based on metals or metal oxides. These properties are ease of external actuation, real-time sense-making, and multitasking, which are required for navigation and control in extremely complex BSs. Figure 1a illustrates generic structures of representative inorganic architectures formed by physical and electrochemical methods, such as template deposition and sputtering [21, 28, 29]. Representative design architectures and fabrication strategies of BNs. (a) Overview of major fabrication approaches, including physical, electrochemical, microfluidic, and self-assembly methods [29]. (b) Microfluidic-based synthesis of compartmentalized polymeric and hydrogel structures with integrated catalytic and magnetic components [29]. (c) Hybrid and inorganic NSs fabricated via self-assembly and surface modification for actuation and therapeutic functions [33]. (d) Biohybrid architectures, including DNA-based assemblies and biomaterial-integrated micro- and nanorobots, offer programmable, biologically derived functionalities [33] Soft materials, by contrast, such as biodegradable polymers, hydrogels, lipid-based assemblies, and polysaccharides, offer greater flexibility, deformability, and biocompatibility. Such properties are especially beneficial in RM and tissue-interfacing devices, where very long residence times and minimal mechanical perturbation are required. DNA-based nanostructures, particularly DNA origami and junction-based assemblies, further expand the design space by enabling programmable control over nanorobot geometry and the spatial localization of functional components, as shown by representative examples in Fig. 1d [29–33]. Fabrication strategies transform material properties into functional nanorobotic structures and significantly affect reproducibility, scalability, and translational capabilities. Top-down processes, such as lithography and template fabrication, are highly precise structurally and are commonly limited by cost and throughput. Scalable production of soft and hybrid systems can be achieved using bottom-up methods, such as chemical synthesis, molecular self-assembly, and microfluidic droplet-based fabrication, e.g., compartmentalized polymeric and hydrogel-based architectures (Fig. 1b) [29, 34]. More and more, hybrid approaches that leverage top-down accuracy and bottom-up scalability are under consideration to strike a compromise between these trade-offs. Table 1 gives a comparative summary of the most frequently used materials, fabrication pathways, and their biomedical applicability [7, 28, 34]. Table 1Comparison of representative nanorobot material systems, fabrication strategies, key physicochemical properties, functional advantages, and their suitability for biomedical applicationsMaterial / System TypeFabrication StrategyKey Physicochemical PropertiesPrimary FunctionsBiomedical ApplicationsMajor AdvantagesKey LimitationsReferenceGold nanorobotsChemical synthesis, templatingPlasmonic, inert, high-density; Size: ~20–200 nm; Drug loading: ~5–15 wt%; Degradation: non-biodegradable (months–years)Optical actuation, imagingPhotothermal therapy, drug deliveryExcellent biocompatibility, imaging contrastHigh cost, limited biodegradability[45, 46]Iron oxide nanorobotsCo-precipitation, thermal decompositionSuperparamagnetic; Size: ~10–150 nm; Drug loading: ~5–20 wt%; Clearance: weeks–months (RES uptake)Magnetic actuation, MRI trackingNavigation, imaging, hyperthermiaDeep-tissue control, clinical familiarityAggregation, long-term retention[47–49]Platinum-based nanomotorsElectrodeposition, chemical growthCatalytic, rigid; Size: ~50–500 nm; Drug loading: <10 wt%; Degradation: negligible (non-biodegradable)Chemical propulsionProof-of-concept propulsionHigh propulsion efficiencyPoor biocompatibility[50, 51]Silica nanorobotsSol–gel synthesisPorous, tunable surface; Size: ~50–300 nm; Drug loading: ~10–30 wt%; Degradation: days–weeksDrug loading, protectionDrug delivery, scaffoldsHigh payload capacityLimited biodegradation[52, 53]Polymeric nanorobots (PLGA, PEG)Emulsion, self-assemblySoft, biodegradable; Size: ~50–200 nm; Drug loading: ~5–25 wt%; Degradation: days–weeks (hydrolytic)Controlled releaseRMHigh biocompatibilityLow mechanical strength[6, 54, 55]Hydrogel-based nanorobotsCrosslinking, microfluidicsSwellable, ECM-mimicking; Size: ~100–500 nm; Drug loading: ~10–30 wt%; Degradation: days–weeksShape adaptationTissue regenerationBiomimetic behaviorSlow response times[6, 56]Lipid-based nanorobotsLiposome assemblyAmphiphilic, flexible; Size: ~50–150 nm; Drug loading: ~5–20 wt%; Clearance: hours–daysEncapsulationDrug/gene deliveryClinical translation experienceStructural instability[57–59]DNA origami nanorobotsProgrammable self-assemblyHigh precision, addressable; Size: ~20–100 nm; Drug loading: ~5–15 wt%; Degradation: hours–days (nucleases)Logic, targetingPrecision medicineMolecular programmabilityEnzymatic degradation[30, 60, 61]Carbon nanotube nanorobotsCVD, exfoliationConductive, high-strength; Size: ~10–100 nm (diameter); Drug loading: ~5–15 wt%; Degradation: very slow (months–years)Electrical actuationNeural interfacesExcellent conductivityLong-term toxicity concerns[47–49]Enzyme-powered nanorobotsSurface immobilizationBiocatalytic; Size: ~50–200 nm; Drug loading: ~5–15 wt%; Degradation: hours–daysSelf-propulsionGI tract navigationUse of endogenous fuelsLimited propulsion force[62, 63]Janus nanorobotsAsymmetric synthesisDirectional properties; Size: ~50–300 nm; Drug loading: ~10–30 wt%; Degradation: variableDirected motionDrug transportEfficient navigationFabrication complexity[20, 64, 65]Shape-morphing nanorobotsStimuli-responsive polymersAdaptive geometry; Size: ~100–500 nm; Drug loading: ~10–25 wt%; Degradation: days–weeksBarrier penetrationECM navigationEnvironmental responsivenessSlow actuation kinetics[57, 59]Swarm nanorobotsCollective self-assemblyEmergent behavior; Size: ~50–500 nm; Drug loading: variable; Degradation: system-dependentCooperative actionLarge-area therapyRobust collective functionCoordination complexity[51, 66]Bacteria-driven biohybridsBiofunctionalizationMotile, chemotactic; Size: ~1–5 μm; Drug loading: ~10–40 wt%; Clearance: hours–daysAutonomous propulsionTumor targetingNatural navigationImmune clearance risk[50, 51]Sperm-driven microrobotsHybrid assemblyFlagellar motility; Size: ~50–100 μm; Drug loading: moderate; Clearance: short-termTargeted deliveryReproductive medicineHigh propulsion efficiencyEthical/control concerns[47, 49]Cell membrane–coated nanorobotsMembrane cloakingBiomimetic surface; Size: ~80–200 nm; Drug loading: ~5–20 wt%; Clearance: days–weeksImmune evasionTargeted therapyProlonged circulationComplex fabrication[64, 65]Magneto-acoustic nanorobotsMultimodal integrationMulti-field responsive; Size: ~50–300 nm; Drug loading: ~10–30 wt%; Degradation: variableHybrid actuationConfined environmentsEnhanced controllabilitySystem complexity[67, 68]Biodegradable metal nanorobots (Mg, Zn)Alloy engineeringControlled dissolution; Size: ~100–500 nm; Drug loading: low–moderate; Degradation: hours–daysTransient operationTemporary therapySelf-eliminationLimited lifespan[7, 69, 70]Soft robotic nanostructuresSoft lithographyDeformable, compliant; Size: ~100–500 nm; Drug loading: ~10–25 wt%; Degradation: days–weeksGentle interactionRegenerative interfacesReduced tissue damageLow propulsion efficiency[7, 71]Hybrid inorganic–organic nanorobotsMultistep integrationMultifunctional; Size: ~50–300 nm; Drug loading: ~10–35 wt%; Degradation: variableCombined tasksClinical translation candidatesBalanced performanceScalability challenges[20, 72] Comparison of representative nanorobot material systems, fabrication strategies, key physicochemical properties, functional advantages, and their suitability for biomedical applications Functional components and modular design In addition to their structural design, nanorobots derive their functionality from a combination of active and passive components within a single nanoscale system. Standard functional components of a design might be propulsion or actuation units, sensing, targeting ligand, and therapeutic or diagnostic payload compartments [20, 35]. The actuation components can be used to achieve controlled movement or positioning in response to external or internal stimuli, and the sensing modules can enable nanorobots to respond to microenvironmental, biochemical, or physical stimuli. Targeting ligands confer specificity for a particular cell or tissue type, and payload compartments allow the encapsulation and targeted release of drugs, genes, or signaling molecules [2, 36]. The principles of modular design have become a useful approach to managing complex systems and improving flexibility. Systematic optimization and configurability of nanorobotic platforms for a wide range of biomedical applications will be achieved by treating each function as a discrete module [37]. It encourages multifunctional, versatile systems, including hybrid inorganic-organic nanorobots and compartmentalized polymeric systems. However, increased modularity also comes with size, component interference, and long-term stability issues. System-level integration must be of high quality, leveraging advances in responsive materials and nanoscale engineering to achieve robust, multifunctional NSs [36, 38]. This MDF also provides the conceptual basis for biohybrid and living NSs, in which biological components are integrated as functional modules to enhance propulsion, targeting, and adaptive behavior. Biohybrid and living NSs Biohybrid and living NSs represent a design strategy that leverages natural biological behaviours by integrating synthetic materials and biological components. Within the MDF described in these systems are more appropriately interpreted as specialized implementations of functional modules rather than as an independent parallel category. Such systems include cells, cell membranes, enzymes, and microorganisms, and employ natural processes such as motility, metabolic activity, sensing, and immune evasion. In this context, biological components can be conceptualized as discrete modules that contribute specific functionalities, such as propulsion, targeting, sensing, or adaptive behaviour, within an integrated nanorobotic system. Examples include nanorobots that harness the power of enzymes, cell membrane-coated systems, and cell-laden micro-scaffold designs that combine biological performance and synthetic control, as in Fig. 1c and d [29, 33, 36, 39]. For instance, bacteria-driven platforms function as biologically integrated propulsion modules. At the same time, cell membrane-coated nanorobots act as biomimetic targeting and immune-evasion modules, further illustrating the modular nature of biohybrid design. Biohybrid systems have new design and translational challenges despite their benefits. Although these systems enhance functional diversity, their integration within modular architectures introduces additional system-level complexity. Biological components are unpredictable and variable, responsive to environmental changes, and therefore difficult to control, which complicates scalable manufacturing and reproducibility. Safety concerns related to immune response, genetic stability, and the longevity of persistence should also be considered. Controllable encapsulation, surface engineering, and synthetic biological interfacing are among the strategies under development to improve controllability and reproducibility, thereby making it more broadly applicable to biomedical systems [40, 41]. Biodegradability and biocompatibility considerations The design of nanorobots for in vivo biomedical applications requires biodegradability and biocompatibility. Nanorobots should be able to perform their intended tasks without causing unacceptable levels of toxicity, inflammation, or immunogenicity [42, 43]. Material composition, surface chemistry, size, and shape strongly influence interactions with BSs, including protein adsorption, immune recognition, cellular uptake, imaging pathways, and clearance pathways. Biocompatible polymers, peptides, or biomimetic coatings are typically used to surface-modify materials and reduce nonspecific interactions, thereby extending circulation time [36, 44]. Biodegradability also addresses the issues of long-term accumulation and chronic toxicity. Ideally, nanorobots are expected to break down into non-toxic, readily excretable byproducts once they have completed their treatment processes. Enzyme-degradable polymers, bioresorbable materials, and stimuli-responsive linkers are under development to enable controlled degradation while maintaining functional stability during use. The clinical translation of biomedical NSs is a critical issue of balancing durability and performance with safe elimination. Key insights A central challenge in nanorobot design lies in balancing biocompatibility and biodegradability with sufficient actuation efficiency and functional robustness. Fully inorganic systems often provide superior actuation performance but suffer from long-term persistence and potential toxicity. In contrast, purely polymeric systems offer enhanced biocompatibility at the expense of mechanical strength and propulsion efficiency. Emerging evidence suggests that hybrid material strategies, particularly biodegradable metal-polymer systems, represent a promising compromise, enabling high-performance actuation followed by controlled degradation into biocompatible byproducts. Additionally, biohybrid approaches incorporating biological components can further enhance immune compatibility and functional adaptability. From a design perspective, future NSs will likely rely on modular multi-material integration, in which structural, functional, and degradation properties are optimized independently. Such hybrid and modular architectures provide a balanced strategy for achieving functionality, safety, and translational feasibility in clinical applications. Propulsion and actuation mechanisms Chemical and enzymatic propulsion mechanisms Among the earliest and most widely studied approaches to the active motion of nanorobots in the biological world are chemical and enzymatic propulsion mechanisms. Those systems are based on catalytic reactions at the nanorobot’s surface, where a local chemical gradient is converted into directed motion via mechanisms such as self-diffusiophoresis, an interfacial tension gradient, or bubble propulsion [73, 74]. Common examples include platinum- or enzyme-functionalized nanorobots that degrade substrates such as hydrogen peroxide, glucose, or urea, thereby generating localized gradients that drive propulsion. Enzyme nanorobots are of particular interest to biomedical devices because they can use physiologically relevant fuels, eliminating the need for externally supplied or potentially toxic reactants and enabling more natural interactions with the biological world [7]. However, it should be noted that propulsion performance strongly depends on substrate availability, which is often limited under physiological conditions. The choice of appropriate enzyme-substrate pairs can be tailored to particular biological niches, including the gastrointestinal system, inflammatory sites, and the microenvironment surrounding a tumor, where endogenous substrates can be highly concentrated. Moreover, enzyme cascades, which co-purify catalytic reactions, are investigated to enhance propulsion efficiency and reactivity [75, 76]. Despite these benefits, there are significant impediments to the in vivo use of chemical propulsion systems. The supply of fuel is limited, efficiency is lower at physiological propulsion concentrations, and reaction byproducts can be toxic, which limits clinical feasibility. In particular, under in vivo conditions, rapid dilution and diffusion of chemical fuels can result in a sudden reduction in thrust and loss of propulsion stability, especially in systems that rely on exogenous substrates. Moreover, chemical gradients decay rapidly in complex biological fluids; they exhibit minimal directional persistence or steering forces. These limitations are further exacerbated in heterogeneous biological environments, where fluid flow and structural barriers disrupt gradient formation and sustained motion. Current developments aim to enhance biocompatibility and catalytic efficacy, particularly under low substrate concentrations and with external direction or targeting, to achieve robustness and controllability [77, 78]. Additionally, the biocompatibility of commonly used fuels, particularly hydrogen peroxide, remains controversial, as concentrations required for effective propulsion may induce oxidative stress, tissue damage, and inflammatory responses. Recent studies have also reported limited in vivo performance or failure of such systems, highlighting the challenge of balancing propulsion efficiency with biological safety. Magnetic, acoustic, optical, and electric actuation The use of externally actuated propulsion strategies enables greater controllability by decoupling the nanorobot’s motion from local chemical conditions. The most studied of these methods has been magnetic actuation due to its deep tissue penetration, long-range functionality, and compatibility with the body. Magnetoreceptor nanorobots can be directed, rotated, or reoriented by homogeneous magnetic fields, field gradients, or rotating magnetic fields, enabling precise navigation through small physiological features such as blood vessels and tissue pores. Figure 2b and f represent the forms and frequency-dependent locomotion modes of the magnetic fields [28, 79–81]. Propulsion, actuation, and navigation mechanisms of biomedical micro/nanorobots. (a) Schematic overview of sensing-enabled micro/nanorobots, illustrating propulsion modes, surface functionalization, sensing elements, and representative biomedical applications [93]. (b) Classification of magnetic actuation fields, including uniform and gradient fields, rotating magnetic fields, oscillating fields, and on-off control schemes [80]. (c) Frequency-dependent locomotion behavior of magnetically actuated microrobots, showing stable synchronized motion and loss of synchronization at higher frequencies [81]. (d) Rolling-based locomotion of magnetically driven microrobots on three-dimensional curved surfaces [81]. (e) Propulsion and spinning modes induced by rotating magnetic fields using coil-based actuation systems [81]. (f) Magnetic microdimer robot with two distinct magnetic distributions, enabling frequency-controlled multimodal locomotion [81]. (g) Time-lapse trajectories demonstrating precise steering and motion control under modulation of an external magnetic field [81]. (h) Conceptual illustration of magnetically actuated microrobots performing minimally invasive cancer cell microsurgery [81] Another noninvasive modality with the potential for deep-tissue penetration and remote control is acoustic actuation, particularly ultrasound propulsion. Examples of such uses include propulsion via acoustic fields, such as acoustic streaming, cavitation, or vibration-induced motion, as well as imaging or therapeutic tasks. Further extensions of the control strategies, providing high spatial precision and fine manipulation, respectively, are optical and electrical actuation approaches [82, 83]. Optical techniques, however, are limited by tissue scattering and absorption and can only be applied to superficial areas. In contrast, electric fields can induce interactions with endogenous bioelectric activity and have to be handled with care regarding safety. Hybrid actuation techniques involving the combination of various external stimuli are under increasing study to achieve a compromise in penetration depth, precision, and safety, and an overall comparison of actuation modalities is outlined in Table 2 [84, 85]. Table 2Summary of representative propulsion and navigation modalities for BNs, highlighting key advantages, limitations, and translational considerationsPropulsion / Actuation ModalityDriving PrincipleEnergy / Control SourceTypical Speed (µm/s)Typical Thrust (pN)Key AdvantagesMajor LimitationsIn vivo FeasibilityPrimary Toxic ByproductsRepresentative ApplicationsReferenceChemical catalytic propulsionAsymmetric fuel decompositionChemical fuel (e.g., H₂O₂)10–3000.1–50High propulsion speedToxic fuels, poor controlLowROS, O₂ bubblesProof-of-concept nanomotors[37, 94]Enzymatic propulsionBiocatalytic reactionsEndogenous substrates0.5–100.01–2Biocompatible fuelsLow propulsion forceModerateNH₃, CO₂, gluconic acidGI tract navigation[95, 96]Bubble propulsionGas generationChemical reaction100–200010–1000High thrustTissue damage riskVery lowGas bubbles (O₂, H₂, CO₂)Experimental demonstrations[97, 98]Self-diffusiophoresisLocal solute gradientsChemical gradients0.1–200.001–1Simple designWeak force in vivoLowReaction-dependent solutesLab-scale studies[37, 94]Magnetic gradient actuationForce from field gradientsExternal magnetic fields1–1000.1–100Deep tissue penetrationRequires hardwareHighNone intrinsicVascular navigation[67, 68]Rotating magnetic helicesTorque-driven rotationRotating magnetic fields10–5000.1–50Precise steeringFabrication complexityHighNone intrinsicTDD[99–101]Magnetic surface rollingFriction-assisted motionExternal magnetic fields10–3000.1–20Stable motion near surfacesLimited free-space motionHighNone intrinsicTissue interfaces[15, 102, 103]Acoustic (ultrasound) propulsionAcoustic streamingExternal ultrasound10–10001–500Non-invasive, deep penetrationHeating concernsHighNone intrinsicMinimally invasive therapy[104]Acoustic bubble oscillationBubble vibrationUltrasound50–150010–1000Strong propulsionControl complexityModerateBubble instability effectsTargeted delivery[15, 105]Light-driven propulsionPhotothermal/photochemicalOptical stimulation1–1000.01–10High spatial precisionPoor tissue penetrationLowROS, thermal effectsSuperficial therapies[64, 65]Electric field actuationElectrokinetic forcesExternal electric fields1–2000.1–20Fine motion controlBioelectric interferenceLow–ModerateElectrolysis productsIn vitro manipulation[67, 68]Shape-asymmetric propulsionGeometry-induced gradientsEnvironmental gradients0.1–100.001–1No external fieldsLow efficiency in vivoLowMinimal (context-dependent)Experimental nanomotors[97, 98]Shape-morphing propulsionStimuli-responsive deformationChemical / thermal cues0.1–500.01–10Barrier penetrationSlow responseModeratePolymer degradation productsECM navigation[106, 107]Surface crawlingAdhesion–detachment cyclesSurface interactions0.1–200.1–10Stable positioningLow speedModerateNone intrinsicTissue interfaces[108–110]Bacteria-driven propulsionFlagellar motilityBiological energy10–1000.1–10Autonomous navigationImmune clearanceModerateEndotoxins, metabolitesTumor targeting[111, 112]Sperm-driven propulsionNatural flagellar motionBiological energy20–2501–100High propulsion efficiencyEthical/control issuesModerateMinimal intrinsicReproductive medicine[113, 114]Cell migration–assistedHost cell motilityCellular machinery0.01–1100–10,000Immune evasionLimited controllabilityModerateCytokines, signaling factorsInflammatory targeting[115, 116]Swarm magnetic controlCollective field guidanceExternal magnetic fields10–50010–10,000Robust collective behaviorComplex controlHighNone intrinsicLarge-area targeting[15, 102, 103]Hybrid chemical–magneticDual-mode propulsionChemical + magnetic10–3000.1–100Improved adaptabilitySystem complexityModerate–HighFuel-related byproductsPrecision therapy[15, 68]AI-assisted navigation*Algorithmic optimizationImaging + computation——Optimized trajectoriesData dependenceEmergingNone intrinsicPrecision interventions[117, 118] Summary of representative propulsion and navigation modalities for BNs, highlighting key advantages, limitations, and translational considerations Self-propelled and biologically driven nanorobots Biologically motivated, self-propelled nanorobots use inherent physical asymmetries (BSs) to generate motion without continuous external control. Interfacial, diffusiophoretic, or thermophoretic can be used to create propulsion by shape-asymmetric nanostructures in the presence of local gradients. Simultaneously, biohybrid systems that use living organisms employ naturally evolved motility strategies that perform well in biologically complex environments [86, 87]. The most notable of them are bacteria-driven nanorobots, which operate via flagellar propulsion and chemotaxis, and sperm-driven micromotors, which harness endogenous flagellar motion for targeted transport and applications in reproductive medicine [74, 88]. Biologically inspired systems exhibit high adaptability, low energy use, and sensitivity to biochemical signals; thus, they can navigate unfavorable environments, a capability that strictly synthetic systems cannot achieve. They also present challenges related to predictability, controllability, and safety [89, 90]. The variability of biological responses, immune recognition, and short lifespan make reproducible functioning and long-term in vivo operation difficult. Genetic modification, physical containment, and hybrid synthetic-biological interfaces are among the strategies used to increase controllability without sacrificing biological functionality. The future development of synthetic biology and biohybrid design is likely to extend the utility of biologically motivated nanorobots for autonomous biomedical applications [91, 92]. While the mechanisms discussed in this section define how motion is generated at the nanoscale, effective operation in complex biological environments also requires higher-level strategies for navigation, decision-making, and environmental interaction. These aspects are addressed in Sect. 4, where control and intelligence frameworks governing nanorobotic behavior are discussed. Navigational stability in low reynolds number biological fluids Navigation and steering of nanorobots in physiological environments present significant physical and biological challenges. At the microscale, these challenges are fundamentally governed by fluid mechanics under low Reynolds number conditions (Re ≪ 1), where viscous forces dominate inertial effects. In this regime, motion is described by Stokes flow, and propulsion must continuously overcome viscous drag (Fd = 6πµRv, where µ is fluid viscosity, R is characteristic size, and v is velocity) [74, 80]. Consequently, propulsion efficiency is strongly constrained by viscous dissipation, and reciprocal motion cannot generate net displacement (Purcell’s scallop theorem), necessitating non-reciprocal actuation mechanisms such as helical rotation or asymmetric surface reactions [74, 80]. In addition to viscous drag, maintaining navigational stability in complex biological fluids such as blood is further complicated by heterogeneous flow conditions, shear gradients, and stochastic forces. Blood is a non-Newtonian fluid containing cells, proteins, and particulates that induce spatially varying viscosity and local disturbances, which can disrupt directed motion. At the nanoscale, Brownian motion introduces random fluctuations that compete with deterministic propulsion, reducing trajectory persistence and targeting accuracy. Moreover, hydrodynamic interactions with vessel walls and cellular components can lead to unintended adhesion or lateral drift. To mitigate these effects, strategies such as externally guided actuation (e.g., magnetic or acoustic fields), anisotropic or helical geometries for enhanced directional stability, and surface functionalization to minimize nonspecific interactions have been explored. These approaches enable more robust control of nanorobot trajectories under physiologically relevant conditions, improving their ability to maintain stable navigation in complex in vivo environments. Control, navigation, and intelligence in NSs Molecular, cellular, and tissue-level targeting In contrast to the propulsion and actuation mechanisms discussed in Sect. 3, which define how motion is generated, this section focuses on how NSs interpret environmental information, make decisions, and direct motion in complex biological environments. Control and intelligence frameworks integrate sensing, navigation, and actuation to enable precise targeting, adaptive behavior, and autonomous operation. Accurate targeting is a key requirement for BNs; the efficiency and safety of therapeutic applications of such technology depend on the localization of the target within complex, dynamic BSs. Molecular-sphere targeting strategies are usually based on functionalizing the surface with antibodies, peptides, aptamers, or small molecules that selectively bind disease-relevant receptors, enzymes, or extracellular surface markers [21, 25, 119]. In this manner, pathological and healthy tissues can be distinguished by nanorobots, and their performance can be optimized by adjusting ligand density and binding affinity, as well as by improving physiological flow environments. There are several multiple- and cooperative-binding strategies to enhance targeting strength in physiological flow environments [120, 121]. Compositional, metabolic, or endocytic differences in the plasma membrane can be used to enable cellular-level targeting, providing specificity without the classical receptor-ligand interaction. For example, selective ingestion of nanorobots by pathophysiological cells can be facilitated by membrane charge, enhanced ingestion, and aberrant metabolic signatures. Other tissue-level targeting employs physiological and anatomic features, such as vascular permeability, ECM framework, interstitial pressure, and pH, oxygen, or nutrient gradients [122, 123]. They may be used particularly for tumors and inflamed tissues, and under non-pathophysiological microenvironmental conditions, selective accumulation may be achieved, as shown schematically in Fig. 3b and d [124–126]. Targeting, sensing, and intelligent control strategies in biomedical micro/nanorobots. (a) Programmable electromagnetic platforms and control schemes for micro/nanorobot navigation, illustrating coil configurations, motion modes, and precision-driven biomedical applications [144]. (b) Modular nanorobot architecture and schematic illustration of TDD across the BBB for brain cancer therapy [125]. (c) Chemically responsive nanorobots for gastrointestinal navigation and oral drug delivery, showing glucose- and chemokine-sensitive behavior and in vivo targeting of inflamed intestinal sites [133]. (d) Swarm-based magnetic nanorobots for tumor targeting, illustrating pH sensing, collective navigation, and controlled drug release in acidic TMEs [126] Despite these advances, in vivo targeting remains challenging due to protein corona formation, immune surveillance, and the progression of disease. These limitations have been addressed by developing strategies that combine active propulsion with adaptive targeting mechanisms, enabling nanorobots to actively chase, anchor, and respond to target locations rather than passively accumulate. Navigation, steering, and control in complex physiological media Nanorobotic motion in physiological media is further influenced by environmental complexity. In biological fluids such as blood, non-Newtonian viscosity, shear-dependent flow behavior, and interactions with cells and macromolecules introduce additional resistance and energy dissipation, significantly reducing propulsion efficiency. Moreover, stochastic forces such as Brownian motion induce random reorientation at small length scales, limiting directional persistence. These constraints highlight the fundamental limitations imposed by the fluid environment on nanoscale actuation. Accordingly, current research focuses on optimizing propulsion mechanisms and structural design to enhance force generation and energy efficiency in heterogeneous and high-viscosity conditions, including the use of helical geometries, surface engineering, and hybrid actuation strategies [81]. Ultrasensitive chemotactic nanorobots have been developed to enable highly efficient and precise tumor targeting through gradient-guided navigation [127]. These processes can be conceptualized within a broader control architecture, where sensing modules provide environmental inputs, decision-making algorithms process this information, and actuation systems execute motion commands. Such integrated frameworks are increasingly enabled by external field modulation, feedback control, and swarm-based coordination strategies, which enhance robustness and functional performance in complex environments [128, 129]. Magnetically driven systems, for example, demonstrate precise trajectory control, frequency-dependent locomotion, and surface-guided motion, highlighting the importance of synchronized actuation and control (Fig. 2c) [81]. These capabilities can be further enhanced through real-time imaging, computational modeling, and advanced algorithmic or artificial intelligence-based approaches, improving navigation accuracy and adaptability for applications in robotic medicine and minimally invasive biomedical procedures [23, 25, 130]. Environmental and biochemical sensing capabilities Sensing enables nanorobots to detect and respond to physical and biochemical signals in their local environment, thereby enabling condition-dependent, context-specific behavior. Environmental sensing is generally sensitive to pH, temperature, redox state, oxygen level, or mechanical forces, which differ markedly between normal and diseased tissues. Nanorobots can be integrated into stimuli-responsive materials or motifs to enable on-demand propulsion, shape changes, or cargo delivery [55, 131]. Biochemical sensing can also be used to make nanorobots dynamically interact with cells and molecules. The selective delivery of therapeutic or diagnostic interventions to disease sites can be achieved using sensors sensitive to enzymatic activity, glucose concentration, inflammatory cytokines, or chemokine gradients [20, 132]. Examples of such mechanisms include chemically sensitive nanorobots that can navigate the gastrointestinal tract and target inflammation (Fig. 3c) [67, 133]. Achieving reliable nanoscale sensing is challenging due to signal noise, poor sensor stability, and interference from complex biological fluids. Current and future developments in nanomaterial engineering, signal amplification, and molecular recognition are improving sensitivity and selectivity, bringing functional in vivo sensing ever closer to clinical reality [134, 135]. Swarm intelligence and collective behaviors Swarm intelligence refers to the coordinated behavior of multiple nanorobots that collectively perform tasks to achieve goals that are inaccessible to individual units. Inspired by natural systems such as bacterial colonies and insect swarms, these systems exhibit collective behaviors (aggregation, dispersion, synchronization, and cooperative transport). Swarm-based strategies in biomedical applications can significantly enhance targeting efficiency by increasing local agent density at disease sites, amplifying diagnostic signals, and improving system robustness against individual nanorobot failure [136–138]. Collective accumulation and coordinated action are particularly advantageous in applications that require high local payload concentration or extensive spatial coverage, such as swarm-based tumor-targeting and drug-delivery models (Fig. 3d). However, implementing swarm intelligence at the nanoscale remains challenging due to limited communication, coordination, and predictability [139]. Communication between nanorobots may occur via chemical signaling, physical forces, or externally applied fields. A combination of inter-robot interactions and environmental feedback is to be finely tuned to enable designable, controllable swarm behaviors. To ensure effective collective behavior, computational modelling and experimental validation are increasingly used to optimize swarm dynamics [70, 140]. Programmable, autonomous, and AI-assisted nanorobots Building upon the navigation and control strategies discussed above, programmable and AI-assisted nanorobots represent an advanced layer of system intelligence, in which decision-making processes are automated and optimized through computational frameworks. Programmability and autonomy are essential for creating intelligent NSs capable of performing multi-step tasks and making smart decisions. The programmable nanorobots may be designed to execute defined logic functions based on measured inputs and to perform a sequence of behaviors: navigation, target detection, activation, and cargo release [141, 142]. Recent work in DNA computing, molecular logic gates, and stimulus-responsive architecture has enabled the first demonstration of decision-making and rule-based control at the nanoscale, as exemplified by modular and programmable nanorobot designs (Fig. 3a) [143, 144]. Artificial intelligence and machine learning are additional capabilities of NSs, enabling adaptive control and system-level optimization. All of this data can be combined to create AI-assisted frameworks that direct the navigation, targeting, and timing of therapy in a closed-loop system. Although most AI computation occurs at the macroscale, when paired with NSs, such algorithms can also enable intelligent behavior that responds to patient-specific, time-varying environments. To commercialize programmable, AI-assisted nanorobots for clinical practice, it will be necessary to address safety, interpretability, and regulatory acceptance [25, 145]. Overall, nanorobotic functionality emerges from the integration of propulsion (Sect. 3) and control (Sect. 4), where actuation provides the physical means of motion, and control systems determine when, where, and how that motion is executed. Remaining Gaps Despite ongoing advances in AI-assisted NSs, the current level of intelligence remains largely limited to stimulus-responsive, externally guided operation rather than true autonomous decision-making. This limitation is primarily attributed to the absence of effective onboard computing, memory, and energy-efficient processing units at the nanoscale, which constrains real-time data processing and independent control. Consequently, most systems rely on externally coupled computation and feedback, where communication delays and limited sensing-actuation integration restrict adaptive performance in dynamic physiological environments. In addition, challenges in high-resolution sensing, signal integration, and robust closed-loop control further limit system-level autonomy. Addressing these gaps will require advances in miniaturized computation, low-power information processing, and tightly integrated sensing-actuation architectures, enabling a transition from externally controlled responsiveness to genuinely autonomous nanorobotic behavior. Although advanced control and targeting strategies enable nanorobots to navigate complex physiological settings, their actual in vivo performance is ultimately constrained by BBs and local microenvironmental conditions. Therefore, the next section examines the major physiological obstacles that govern nanorobot transport, penetration, and functional access before discussing how these processes can be monitored and evaluated in vivo. Interaction of nanorobots with BBs and microenvironments It is intrinsically limited by nanorobot-nanorobot interactions, nanorobot-BBs, and microcompartments within complex tissues, and it underlies their effective functioning in vivo. Unlike in vitro or simplified model systems, the human body is dynamic, heterogeneous, and multiscale, potent determinants of nanorobot transport, localization, and functional performance [146, 147]. Dynamics of blood flow, ECM architecture, presence of epithelial and endothelial barriers, and disease-specific microenvironmental conditions determine whether nanorobots can reach target sites and perform their intended functions. These include not only the systemic circulation but also the tissue interface and intracellular compartments, summarized schematically in Fig. 4 [20, 148]. BBs and microenvironmental constraints affecting nanorobot performance in vivo. (a) Major physiological barriers encountered by chemically powered, externally actuated, and biohybrid nanorobots [155]. (b) Vascular, ECM, and cellular barriers governing tissue penetration and transport. (c) Disease-specific transport limitations, including immune clearance, abnormal perfusion, and restricted intracellular access These barriers are of interest to RM and to minimally invasive interventional use with respect to knowledge and design. Efficient nanorobots require integrating fluid mechanics, materials science, immunology, and tissue biology to ensure they operate in vivo, remain safe, and remain biocompatible [6, 149]. Bloodstream dynamics and vascular transport In the case of nanorobots injected into the bloodstream, the environment is highly dynamic, with blood flow, shear forces, pulsatile flow, and cellular components, all of which impose severe transport constraints. There is a difference in blood flow velocity through the vascular system: the faster the flow, the less organized it is in capillaries and microvessels. The motion of nanorobots may also be dominated by small length scales, Viscous drag, Brownian motion against propulsion or external actuation, and hydrodynamic forces [150, 151]. Recent work further demonstrates that ultrasmall enzyme-powered Janus nanomotors can retain active propulsion and functional performance even within blood circulation systems, highlighting the feasibility of nanorobot operation under physiologically relevant vascular conditions [9, 138, 152]. These nanomotors have demonstrated sustained propulsion and functional performance within blood circulation systems under physiological conditions. Vascular transport is also complicated by contact with blood components. Margination along vessel walls and platelet aggregation may favor nonspecific adhesion, and plasma proteins adsorb rapidly to nanorobot surfaces, altering their size, charge, and biological identity [153, 154]. A major limitation is the clearance by the mononuclear phagocytic system. It reduces the circulation and efficient supply (Fig. 4c) [146]. In part, active nanorobots can overcome these problems through propulsion mechanisms or external magnetic or acoustic guidance that counteract flow forces to achieve maximum vascular targeting (Fig. 4a) [155]. However, excessive use of vascular components can lead to immune or thrombogenic complications. A trade-off among transport efficiency, targeting precision, and hemocompatibility remains a design problem [26, 55]. ECM penetration and tissue interface navigation Beyond the vasculature, nanorobots come into contact with the ECM, a dense, heterogeneous mesh of collagen fibers, proteoglycans, and glycoproteins that transduce mechanical and biochemical signals. The ECM is a major physical obstacle to nanoscale transport, particularly in fibrotic tissue, solid tumors, and scarred tissues, where the matrix density, stiffness, and interstitial fluid pressure are elevated (Fig. 4b) [156]. These properties are anti-diffusive. They can be highly influential in determining the extent of diffusion of passive delivery systems [26]. Active nanorobots offer advantages over passive nanocarriers, including the ability to move in a defined direction by exploiting ECM structures. This concept is supported by recent studies showing that actively propelled nanorobots can penetrate dense tumor barriers more effectively than passive nanosystems, thereby improving intratumoral transport and therapeutic access [89, 157, 158]. The anisotropy of the shape, mechanical flexibility, and surface functionalization to promote matrix-interacting or matrix-remodeling components might enable navigation between tissue interfaces [55, 159, 160]. RM may also benefit from controlled interactions with the ECM, with nanorobots useful for controlling matrix localization or for transporting angiogenic and tissue-remodeling signals. However, one should not excessively disrupt the ECM, as this may cause tissue damage and trigger an inflammatory response. Therefore, there is a need to develop nanorobots that modulate function during tissue penetration and repair of homeostasis [161, 162]. Crossing BBs (BBB, Mucus, Epithelium) There are anatomical constraints that require strict limits on the transport of nanorobots. Through specialized endothelial junctions, transporter systems, and active efflux mechanisms, the BBB has stringent control over molecular and cellular trafficking into the central nervous system [163, 164]. Similarly, the respiratory and gastrointestinal tracts have mucus layers that restrict the entry of foreign material and shield internal organs, while the skin’s epithelial barriers prevent penetration by external objects [20]. Recent studies have shown that orally administered nanorobots can actively overcome intestinal mucus barriers, thereby enabling improved gastrointestinal transport and targeted delivery [165]. A combination of size optimization, surface engineering, and active transport can overcome such barriers using nanorobots. To facilitate improved barrier penetration, ligand-mediated transcytosis, charge modulation, mucus-penetrating coats, and bioinspired surface chemistries have been investigated [166]. Active and external propulsion could also decrease residence time in barrier layers, increasing the likelihood of a successful crossing (Fig. 4a) [155]. However, when protective barriers are compromised, serious safety issues arise, especially when breaches occur in sensitive tissues like the brain. Possible solutions include plans that enable transient, discrete, and reversible interactions between barriers to reduce risk without compromising access to therapy [167]. Disease-specific microenvironmental constraints Disease induces substantial changes in the local microenvironment, presenting both challenges and opportunities for nanorobots. Abnormal vascular architecture, heterogeneous perfusion, acidic pH, hypoxia, high enzyme activity, and widespread inflammatory cell infiltration are common to tumors, inflamed tissues, and injury sites. These attributes can slow the homogeneous distribution of nanorobots and also provide biochemical signals for targeting or activating them (Fig. 4c) [146, 168]. In cancer, for example, acidic or hypoxic environments can reduce the propulsion ability of certain nanorobots but enable pH- or enzyme-sensitive drug delivery. Microenvironments in RM are dynamic, encompassing inflammatory and reparative stages during which biochemical and mechanical characteristics vary. Nanorobots used in this context should be able to respond to temporal changes to be effective. Failure to account for disease-specific microenvironmental constraints can lead to reduced efficacy, undesirable immune reactions, or off-target responses. Therefore, there is a pressing need to introduce microenvironment-responsive design into NSs to enable robust operation across a wide range of pathological and regenerative environments [169]. Imaging and real-time monitoring of nanorobot navigation across BBs Once the principal BBs and microenvironmental constraints are defined, imaging and tracking become essential tools for monitoring, in real time, how nanorobots navigate, penetrate, and respond within these environments. Beyond simple localization, imaging provides dynamic feedback on barrier crossing, tissue penetration, target engagement, and treatment progression, thereby linking physiological obstacles to measurable in vivo behavior. In vivo tracking and imaging of nanorobots require efficient methods to assess their delivery, therapeutic efficacy, and safety. Unlike passive nanocarriers, nanorobots are not only active and stimulus-responsive but, in some cases, also collective or autonomous; hence, real-time observation is particularly essential [26]. The imaging technologies not only provide insight into biodistribution and target engagement but also enable control of feedback, dose optimization, and safety evaluation. Hence, both preclinical evaluation and clinical translation of NSs use imaging and tracking methods [170]. In addition to visualization, imaging can be used to communicate with nanorobots and external control systems. Real-time feedback enables researchers and clinicians to adjust actuation parameters, verify target localization, and monitor treatment progress. Figure 5 summarizes the first category, which is representative of imaging-guided nanorobot platforms [145]. Imaging and real-time tracking of nanorobots and microrobots in vivo. (a) Au/Pt nanomotors for tumor targeting and photoacoustic imaging, illustrating vascular navigation, NIR activation, and enhanced imaging signals in tumor tissue [173]. (b) NIR-activated Au/TiO2 nanomotors showing catalytic activity and time-dependent photoacoustic imaging of liver tumors in vivo [173]. (c) Modular enzymatic nanomotors for bladder imaging, combining mesoporous silica, enzyme propulsion, and near-infrared contrast agents to enhance local diffusion and imaging [173]. (d) Mg-Au micromotors with drug and polymer layers for gastrointestinal delivery, enabling NIR-guided photoacoustic computed tomography imaging in the stomach and intestine [173]. (e) Microrobots loaded with ultrasound contrast agents for enhanced ultrasound imaging [180]. (f) Real-time ultrasound tracking of microrobot motion in tubular environments, demonstrating controlled directional movement over time [180]. (g) Optical absorbance characterization of ultrasound contrast agent loading as a function of concentration [180]. (h) Quantitative analysis of ultrasound contrast agent loading within microrobots [180] Imaging modalities for monitoring barrier crossing and tissue penetration Numerous imaging modalities have been investigated to monitor nanorobot behavior in vivo, each with its own benefits and inherent limitations. Optical imaging modalities, such as fluorescence and photoacoustic imaging, are of particular interest in preclinical research owing to their high sensitivity, relative simplicity, and compatibility with a wide range of nanomaterials [171, 172]. These methods enable real-time observation of nano-robots in surface tissues and small animals, e.g., for tumor macro-penetration and nanorobot navigation through tumor tissue (Fig. 5a, b) via photoacoustic imaging [173]. Their use, however, is limited by tissue penetration, optical scattering, and photobleaching, which preclude their application in deep-tissue or clinical imaging [174]. Magnetic resonance imaging (MRI) has also been of interest for tracking magnetic-responsive nanorobots, as it provides deep tissue penetration and high spatial resolution without ionizing radiation. This can be achieved using magnetic components that enable both actuation and imaging, as well as localization and closed-loop navigation [175]. Nuclear imaging methods such as PET and SPECT are exceptional for their sensitivity and the ability to track the whole body over extended periods. Nanorobots radiolabeled with a single isotope allow accurate determination of biodistribution and clearance; however, their spatial resolution is very low, and radioactive tracers have regulatory and safety implications [176, 177]. Multimodal and theranostic tracking for feedback-guided navigation Multimodal imaging approaches are now used to enable nanorobot tracking and to overcome the shortcomings of individual imaging techniques. By combining contrast agents within a single nanorobot, one can integrate complementary imaging properties, e.g., the sensitivity of nuclear imaging with the spatial resolution of MRI or the temporal resolution of optical and ultrasound approaches. Multimodal systems enable cross-validation of localization data and provide a more detailed view of nanorobot behavior at spatial and temporal scales [178, 179]. Notably, imaging datasets offer a valuable opportunity to serve as quantitative inputs for PBPK modelling. For instance, PET and SPECT imaging enable time-resolved, whole-body quantification of radiolabeled nanorobot concentrations, while MRI and fluorescence imaging provide high-resolution spatial information on tissue accumulation. When integrated within a PBPK framework, these data can facilitate the estimation of key model parameters, including tissue partition coefficients, clearance rates, and organ-specific accumulation kinetics. Theranostic nanorobots also combine imaging and therapeutic capabilities within a single platform. Under these systems, imaging signals can provide real-time feedback on nanorobot distribution, activation state, and therapeutic response, and support adaptive, personalized intervention methods. Beyond real-time monitoring, this feedback enables iterative calibration and validation of PBPK models by comparing predicted versus observed biodistribution profiles. Examples of real-time visualization used to enhance precision therapy and MIIs include imaging-guided gastrointestinal delivery, bladder imaging, and ultrasound monitoring of a microrobot’s movement (Fig. 5c-f) [173, 180]. Furthermore, multimodal imaging facilitates cross-validation of PBPK predictions across different spatial and temporal scales, thereby improving model robustness and reducing uncertainty in simulated transport and pharmacokinetic behavior. Although these methods improve functionality, a more complex system may complicate fabrication, signal analysis, and regulatory assessment. The design thus needs to be carefully crafted to mitigate multifunctionality while preserving robustness and translational feasibility [181]. Current limitations in spatiotemporal resolution and quantitative monitoring Although the efficiency of nanorobot imaging and tracking has yet to be achieved, it can be argued that, despite significant progress, current methods can only mitigate obstacles that hinder the efficacy of these techniques. The spatial resolution is still insufficient to detect individual nanorobots in deep tissues and at the nanoscale; therefore, they must use ensemble or population measurements. Clinically relevant doses may also go undetected because sensitivity limitations prevent detection of signals, particularly when signals are lost due to dispersion, degradation, or clearance [182, 183]. The interpretation of imaging data cannot be done quantitatively, even more so. Signal levels are not always correlated with nanorobot concentration, activity, or therapeutic activity; therefore, dose-response and performance analyses are difficult. Other confounding factors that lead to inaccurate quantification include motion artifacts, tissue heterogeneity, and biological noise. These problems are especially severe in dynamic imaging, such as ultrasound and photoacoustic imaging, where motion and environmental changes can be detected from signal variations (Fig. 5f-h) [180, 184, 185]. It is through the development of imaging probe designs, signal-processing algorithms, and standardized quantitative models that such drawbacks will be addressed. Further advances, combining imaging, computational modelling, control, and artificial intelligence, will enable more credible and translational nanorobot-monitoring technologies [134, 186]. Dynamic in vivo performance, biodistribution, and biosafety of nanorobots After defining the main BBs and the imaging approaches used to monitor nanorobot transport, the next question is how these systems actually behave in vivo. Their biodistribution, persistence, immune interactions, degradation, and safety profiles determine whether successful navigation across physiological barriers translates into meaningful therapeutic performance. The in vivo performance of nanorobots encompassing biodistribution, immune interactions, degradation, and safety is a key determinant of their clinical translation. Nanorobots exhibit active motion, environmental sensitivity, and, in some cases, autonomous or semi-autonomous behavior, which distinguishes their biological fate from that of passive nanocarriers [187]. They are dynamic properties that influence the circulation time, tissue accumulation, cellular interactions, and clearance pathways, and are not well represented in the classical pharmacokinetic and nanotoxicology models. Therefore, integrated experimental and computational frameworks are required to characterize nanorobot behavior in vivo accurately. This suggests that experimental and computational models must be combined to test nanorobot behavior in vivo and to account for both passive transport and active control [188]. Knowledge of nanorobots’ distribution within the body, their mechanical interactions with BSs, and their degradation under various conditions is important for assessing the therapeutic efficacy, safety, and long-term clinical viability of nanorobots. Organ-specific accumulation, immune interactions, and excretion routes are studied at the system level rather than from a limited perspective of short-term efficacy. One example of a representative evaluation method and outcome is presented in Fig. 6 [189]. In vivo performance, biodistribution, and biosafety assessment of NSs. (a) Integrated in vitro-to-in vivo extrapolation framework illustrating biodistribution, metabolism, adsorption, and excretion of nanorobots using PBPK and ADMET models [196]. (b) In vivo fluorescence imaging and biosafety comparison of surface-engineered nanomaterials, showing tumor accumulation, retention, hepatobiliary excretion, and toxicity outcomes [194]. (c) Fabrication, physicochemical characterization, and radiolabeling of enzyme-powered nanomotors, including surface functionalization, size and charge analysis, and radioactivity profiling before and after purification [195] Pharmacokinetics and biodistribution profiles Pharmacokinetics and biodistribution expound the process by which nanorobots are absorbed, distributed, retained, and eliminated by the body after administration. They are size, shape, surface chemistry, mechanical properties, and nature of functional payloads. It has been demonstrated that nanorobots can exhibit altered circulation patterns, either through active propulsion or external activation, rather than passive nanoparticles, thereby enabling prolonged residence time or enhanced permeabilization of previously inaccessible tissues. These moving processes complicate the modelling of traditional pharmacokinetics, as diffusion, convection, and blood circulation are no longer the only factors that control transport [190, 191]. The biodistribution of the nanorobot can be assessed using multimodal imaging modalities, primarily magnetic resonance imaging, fluorescence imaging, PET, and photoacoustic imaging. These tools enable real-time localization, persistence, and clearance of nanorobots within organs, as demonstrated by radiolabeled and fluorescent nanorobot systems (Fig. 6b, c) [192–195]. The combination of imaging information with PBPK and ADMET modeling provides quantitative information on tissue accumulation, residence times, and elimination pathways (Fig. 6a) [196]. This integrated analysis is vital for optimizing dosing, predicting the therapeutic window, and reducing off-target exposure. However, interspecies variation, pathologies, and routes of delivery remain extremely challenging, and standard biodistribution evaluation processes specific to current nanorobotics must be applied [197, 198]. Immune interactions and clearance mechanisms The immune system critically governs nanorobot persistence and functional lifetime. When nanorobots are exposed to biological fluids, a protein corona quickly forms around them, shaping their biological identity and strongly influencing immune cell recognition. The mononuclear phagocytic system, particularly macrophages in the liver and spleen, is the primary mechanism for trapping and eliminating nanorobots from the circulation. Immune recognition and clearance kinetics are sensitive to surface properties, including charge, hydrophilicity, and biomimetic or stealth coating, among others [199, 200]. To partially attenuate nonspecific immune capture, active motion and site-specific retention strategies can be used to decrease systemic exposure or facilitate rapid localization of the target tissue. However, immune interactions cannot be completely avoided, and in certain situations, they may be beneficial to therapy. For example, the controlled interaction of the immune system can be used to promote immunomodulation, tumor immunotherapy, or regenerative signaling [201, 202]. Nonetheless, overactivation of the immune system can be dangerous, including inflammation, tissue damage, and hypersensitivity, as comparative in vivo toxicity studies of various surface-engineered nanomaterials reveal (Fig. 6b) [194]. Long-term immune effects, including immune memory development and responses to repeated dosing, remain poorly defined in nanorobotics. The immune interactions with nanorobotics should be thoroughly assessed to optimize functional performance and biosafety [203]. Toxicity, biodegradation, and long-term safety assessment In-depth toxicity and long-term safety testing require systematic preclinical and translational evaluation frameworks that integrate pharmacokinetics, biodistribution, and material metabolism. There is a risk of toxicity due to inherent material content, mechanical exposure to tissues, degradation products, or off-target retention. While acute toxicity tests assess cytotoxic, organ-specific, and inflammatory responses, long-term safety is governed by chronic exposure, bioaccumulation, and clearance kinetics across major organs. Nanorobots are dynamic, living processes that require more comprehensive safety models that account for interactions arising from motion, repetitive actuation, and long-term tissue interactions [204]. A critical determinant of long-term safety is the metabolic fate and biodegradation of active materials. Ideally, nanorobots are expected to remain structurally and functionally sound throughout their operational period and then degrade into non-toxic, excretable elements [65]. However, commonly used functional components, such as noble metal catalysts (e.g., Pt, Au) and magnetic cores (e.g., Fe3O4), undergo complex in vivo transformations, including dissolution, oxidation, and protein-mediated surface modification, which directly influence their pharmacokinetics and clearance. Following systemic administration, these materials are predominantly sequestered by the mononuclear phagocytic system, leading to accumulation in the liver and spleen. At the same time, renal clearance governs the elimination of ultrasmall degradation products. In certain cases, partial translocation across BBs may result in secondary accumulation in sensitive organs such as the kidneys and brain, raising concerns regarding long-term retention and neurotoxicity. Radiolabeling and longitudinal imaging methods allow tracing of degradation and clearance pathways over time, providing useful information on long-term fate and safety (Fig. 6c) [195]. Chronic toxicity mechanisms are closely linked to material persistence and may include oxidative stress, inflammatory activation, disruption of cellular homeostasis, and impairment of organ function. These risks are further exacerbated under repeated dosing conditions, where incomplete clearance can lead to progressive accumulation and altered immune responses. Therefore, a comprehensive evaluation of dose-dependent pharmacokinetics, repeated-exposure effects, and long-term biodistribution is essential. It should thus be prioritized in establishing standardized, nanorobot-specific safety assessment protocols to ensure reproducibility, comparability, and ultimately regulatory acceptance [66]. These considerations provide a critical foundation for optimizing nanorobot design and ensuring safe clinical translation, as discussed in the following sections. Nano-bio interface interactions in biological fluids The nano-bio interface critically governs nanorobot fate following systemic administration by modulating circulation, transport, and biodistribution. Within the bloodstream, transport is governed by physicochemical properties such as size, shape, and surface charge, as well as hemodynamic forces, including shear stress and flow dynamics [205, 206]. Interactions with blood components further influence margination, adhesion, and targeting efficiency. Upon exposure to biofluids, nanorobots rapidly acquire a protein corona that redefines their biological identity and alters surface characteristics, thereby impacting vascular interactions and functional performance [133, 207]. These processes collectively determine circulation stability and site-specific accumulation. Concurrently, immune recognition plays a central role in regulating nanorobot persistence. Opsonization promotes uptake by the mononuclear phagocytic system, particularly by macrophages in the liver and spleen, thereby reducing circulation time [55, 208]. Surface engineering strategies, including hydrophilic and biomimetic coatings, can mitigate immune clearance, although complete evasion is not achievable. Controlled immune interactions may be leveraged for therapeutic benefit, whereas excessive activation can induce inflammation and toxicity [50, 209]. A mechanistic understanding of nano-bio interface dynamics is therefore essential to balance transport efficiency, targeting precision, and biosafety, ultimately enabling effective clinical translation [138, 210]. Applications of nanorobots in RM Tissue repair and regeneration Nanorobots offer novel approaches to improving tissue repair and regeneration by enabling high spatial and temporal control over therapeutic applications. In tissues such as bone, cartilage, cardiac muscle, and neural tissue, regeneration is frequently constrained by the absence of bioactive cue delivery, inadequate integration with host tissue, and insufficient vascularization [211]. Nanorobots will be able to actively move to injury sites and deliver growth factors, cytokines, or ECM-modulating agents that diffuse through conventional systems. They are small and aggressive, making them easy to penetrate dense or poorly vascularized tissues and access areas that would otherwise be difficult to reach [212, 213]. Recent articles report the application of magnetically actuated, biodegradable microrobots for musculoskeletal repair (cartilage and bone), cardiac tissue repair following ischemic injury (Fig. 7a-c), and other applications [214, 215]. In addition to selective transport, nanorobots can dynamically respond to the regenerative microenvironment. In response to local biochemical, mechanical, or inflammatory signals, they can induce angiogenesis, regulate matrix stiffness, or remove inhibitory debris that hinders healing. Exosome-based hydrogels delivered by nanorobots in the cardiovascular field have shown promise in reducing fibrosis, enhancing cardiomyocyte survival, and inducing neovascularization (Fig. 7b) [211, 214, 216]. Nanorobot-assisted strategies for tissue repair and regeneration. (a) Representative micro/nanorobots designed for bone, cartilage, muscle, and tendon repair, including magnetic Janus, porous, helical, achiral, biodegradable, and chemically powered microrobots [214]. (b) Exosome-loaded hydrogel systems for cardiovascular regeneration, illustrating injectable and patch-based delivery, controlled exosome release, and therapeutic effects on cardiac fibrosis, cardiomyocyte survival, inflammation, and angiogenesis [214]. (c) Micro/nanorobot-enabled regeneration of bone, cartilage, and muscle tissues, showing in vitro niche formation, in vivo joint repair, and near-infrared (NIR)-guided targeting and stimulation [215]. (d) Magnetically guided microrobot and scaffold platforms for regenerative therapy, including SPION-coated systems, programmable magnetic control modes, and computer-aided design and fabrication of 3D microstructures [218]. (e) AI-assisted and magnetically actuated microrobots demonstrating adaptive locomotion, controlled navigation, and real-time motion tracking under external magnetic fields [218] Despite these advances, there remain difficulties in maintaining adequate retention of injury sites and in coordinating nanorobot activities with the temporal stages of tissue repair. To ensure that active interventions do not interfere with physiological healing, a nanorobotic system that aligns with the principles of regenerative biology and delivers growth factors and immune regulators sequentially is necessary [217]. Stem cell guidance and microenvironment engineering RM works around stem cell-based therapies, which are often marred by poor homing of cells, poor survivability, and undesirable differentiation after transplantation. Nanorobots offer new possibilities for directing stem cells to target tissues and for creating supportive microenvironments at the local level [219]. Nanorobots can provide chemotactic stimuli, adhesion factors, or niche conditions that increase the recruitment and maintenance of stem cells by sensing local biochemical gradients and responding dynamically [220]. In addition to directing stem cell localization, nanorobots can actively modulate the stem cell microenvironment to promote survival and lineage commitment. Platforms made of nanomaterials have been demonstrated to modulate intracellular signaling pathways, control cell-material interactions, and externally stimulate stem cell differentiation to trigger osteogenic, chondrogenic, or neurogenic lineages (Fig. 8a, c) [221, 222]. This enables better control through microenvironment engineering than with passive scaffolds alone, particularly in complex or inflamed tissues [28]. Nanorobot- and nanomaterial-based modulation of cellular behavior for RM. (a) Overview of metal-based, carbon-based, and hybrid nanomaterials used to regulate intracellular processes, cell-material interactions, and external stimulation, enabling directed stem cell differentiation [221]. (b) pH-responsive nanomaterial systems enabling controlled ion release, angiogenic signaling, and cytoprotective effects, with schematic illustrations of in vitro mechanisms and in vivo therapeutic outcomes [222]. (c) Nanomaterial-mediated enhancement of cell proliferation, illustrating protein adsorption and activation of MAPK/ERK and calcium signaling pathways on engineered substrates [222]. (d) Nanoparticle-based non-viral gene delivery systems, showing receptor-mediated endocytosis, intracellular disassembly, cytosolic release of genetic cargo, protein expression, and apoptosis induction [224] Nevertheless, it is difficult to organize nanorobot behavior and stem cell dynamics. The long-term safety, consistent differentiation, and scalability of nanorobot-assisted stem cell therapies warrant further investigation. Clinical translation will require robust control over nanorobot degradation, clearance, and interactions with host tissues [223]. Microenvironmental regulation in regenerative contexts In regenerative medicine, precise modulation of the local microenvironment is essential to facilitate tissue repair and functional recovery. NSs can contribute to this process by regulating biochemical and cellular interactions within the target site. Nanorobots can support stem cell recruitment and activation by generating localized biochemical cues and enhancing cell–microenvironment interactions. In addition, they can ECM remodeling through targeted interactions with structural proteins or enzymatic regulation, thereby improving tissue integration and mechanical stability.Nanorobotics is most useful in RM, where localized modulation of cellular behavior and signaling pathways can promote tissue regeneration while minimizing off-target effects (Fig. 8d) [224]. Furthermore, NSs can modulate immune responses by influencing cytokine signaling and inflammatory pathways, thereby creating a favorable regenerative microenvironment. However, challenges related to system stability, controllability, and clinical translation remain. Future efforts should focus on improving the robustness and scalability of nanorobotic platforms for effective microenvironmental regulation [225, 226]. Immunomodulation and inflammation regulation Immune responses affect tissue regeneration; excessive inflammation or prolonged immune responses can impede healing, whereas a balanced immune response can promote healing and reorganisation. Nanorobotic immunomodulation can be understood within a unified framework encompassing both innate and adaptive immune responses, enabling coordinated regulation of immune activity across multiple biological scales. Nanorobots enable localised immunomodulation by interacting with immune cells and regulating signaling pathways in inflamed or damaged tissues [211]. Nanorobots can alter their behavior and release therapeutic agents in response to pathological inflammation by sensing inflammatory cues, including reactive oxygen species, cytokines, and acidic pH [227]. At the innate immune level, nanorobots can modulate macrophage polarization, regulate inflammatory signaling, and control cytokine release, while at the adaptive level, they can influence antigen presentation and T-cell activation, thereby enabling more targeted and sustained immune responses. Nanorobot-based dynamic regulation of inflammation is particularly applicable to chronic injuries, cardiovascular disease, and degenerative diseases, which are characterized by dysregulated immune responses. For example, nanomaterial-based systems have been shown to inhibit apoptosis and excessive immune responses, and to stimulate angiogenesis in injured tissues (Figs. 7b and 8b) [222, 228]. Nonetheless, immune modulation must be carefully adjusted, as unwanted suppression of immune responses or their excessive stimulation may pose a safety risk. Strict screening of immune interactions, dosing regimen, and chronic effects is thus critical in the exploitation of nanorobots as potent immunomodulatory adjuvants in RM [229]. Delivery-related functionalities are discussed in Sect. ""Imaging and Real-Time Monitoring of Nanorobot Navigation Across BBs"". Nanorobots for minimally invasive biomedical interventions TDD and precision therapy One of the most developed and clinically significant applications of BNs is TDD in minimally invasive medicine. Traditional systemic therapies often exhibit poor localization, off-target toxicity, and low therapeutic efficacy at disease sites [6, 15]. Nanorobots overcome such shortcomings by proactively targeting pathological sites and delivering therapeutic cargos in a spatially and temporally controlled manner. In this context, NSs provide a unified platform for controlled, targeted delivery of therapeutic agents, consolidating delivery-related capabilities within precision medicine frameworks. Nanorobots can overcome obstacles to physiological delivery by incorporating propulsion, ligand delivery, and environmental sensing, thereby increasing local drug concentrations and decreasing systemic exposure [133, 145]. Precision Therapy Nanorobots also provide more than space-specific drug delivery: conditional and on-demand delivery. This capability extends beyond conventional delivery approaches by enabling dynamic and adaptive therapeutic control. Nanorobots can be programmed to respond to endogenous stimuli (e.g., pH, enzymes, redox) or to externally applied magnetic, optical, or acoustic fields [233, 234]. This stimuli-responsive behavior enables therapeutic agents to be released only when the disease is relevant, reducing adverse reactions while enhancing the therapeutic index (Fig. 9a, c) [20, 235]. Such stimuli-responsive and programmable delivery mechanisms distinguish NSs from passive carriers by enabling precise spatiotemporal regulation of therapeutic action in complex physiological environments. Although these are the benefits, there are difficulties in achieving sufficient payload capacity, in vivo stability during navigation, and repeatability of patient behavior. In addition, challenges related to delivery efficiency, controlled release consistency, and scalability remain critical barriers to clinical translation. To overcome these shortcomings, better materials, greater fabrication consistency, and control measures will be needed to develop nanorobot-based targeted therapies into standard clinical practice (Table 3) [20, 67]. Future developments should focus on improving delivery precision, enhancing payload integration, and strengthening system robustness to enable reliable and reproducible nanorobotic therapies. Nanorobot-enabled TDD, tumor penetration, and cancer therapy. (a) Overview of nanorobot propulsion mechanisms and application modes, including magnetic, chemical, light-driven, and ultrasound-assisted actuation, enabling drug delivery, phototherapy, detoxification, organelle targeting, and biosensing [20]. (b) Representative administration routes for nanorobots, illustrating ocular, oral, nasal, and topical delivery for localized and minimally invasive treatments [236]. (c) Stimuli-responsive nanorobots for cancer therapy, showing NIR-triggered drug release, catalytic activity, acoustic manipulation, and in situ immunoactivation within tumor tissues [235]. (d) Catalytically powered nanorobot propulsion and enhanced tumor penetration, illustrating active motion, deep intratumoral infiltration, and interaction with three-dimensional tumor models [237]. (e) Time-dependent fate of nanorobot-treated tumor spheroids, demonstrating progressive penetration, intracellular drug release, and tumor disruption over 0–72 h [237]. (f) Tracking trajectories of nanorobots in different biological media, highlighting the effects of environmental composition on mobility and transport efficiency [237]. (g) Intracellular uptake and drug release pathways, illustrating endosomal trafficking, lysosomal uncapping, pH-triggered drug release, and cytotoxic action [237]. (h & i) Illustration of targeting DOX-loaded nanobot to transferrin/EpCAM receptor and entry in cancer cell, and finally, mechanism of triggered drug release under intracellular endo/lysosomal conditions [237] Table 3Nanorobotic applications organized by disease type with preclinical models and primary efficacy endpointsDisease TypeApplicationNanorobot Type / MechanismTarget / FunctionPreclinical ModelPrimary Efficacy EndpointsKey AdvantagesReferenceCardiovascularThrombolysisMagnetic nanorobotsClot degradationMiceClot dissolution; blood flow restorationTargeted thrombus removal[138]AtherosclerosisMagnetic microrobotsPlaque targetingMicePlaque reduction; lipid clearanceLocalized therapy[173, 180, 181]Myocardial infarctionHydrogel–nanorobot hybridsCardiac repairMiceInfarct size reduction; functional recoveryEnhanced angiogenesis[108, 109]OncologyTargeted drug deliveryCatalytic / magnetic nanorobotsTumor cellsMiceTumor volume reduction; survival rateHigh specificity[67]TME modulationBiohybrid nanorobotsImmune & hypoxic regulationMiceImmune activation; hypoxia reductionMulti-functional therapy[176, 177]Metastatic cancer therapyMagnetic swarm nanorobotsTumor disseminationMiceMetastasis suppression; tumor inhibitionEnhanced penetration[67]NeurologyBrain tumor targetingMagnetically guided nanorobotsBBB drug deliveryMiceDrug accumulation; tumor inhibitionCNS targeting[29–33]Neural regenerationPolymeric / biohybrid systemsNeuron repairRatsAxonal growth; functional recoveryRegenerative support[52, 53]Neurodegenerative disordersBiohybrid nanorobotsNeural protectionMiceNeuronal survival; behavioral recoveryDisease modification[217, 218]Spinal cord injuryMagnetic nanorobotsTissue regenerationRatsMotor function recovery; tissue repairFunctional restoration[219]GastrointestinalGI therapyEnzyme-powered nanorobotsGI tractMiceDrug retention; mucosal penetrationBiocompatible propulsion[126, 133, 207, 230]Inflammatory DiseasesInflammatory bowel diseaseStimuli-responsive nanorobotsImmune modulationMiceCytokine reduction; inflammation suppressionControlled immune response[229, 231, 232]Wound / SkinWound healingPolymeric nanorobotsTissue repairMiceHealing rate; tissue regenerationAccelerated recovery[220]OcularDiabetic ulcersSwarm nanorobotsChronic wound repairMiceUlcer closure; vascularizationImproved healing[221–223].Ocular diseasesMagnetic microrobotsLocalized deliveryRabbits / miceDrug retention; vision improvementPrecision targeting[178, 179]RespiratoryLung diseasesBiohybrid nanorobotsPulmonary deliveryMiceDrug deposition; inflammation reductionNon-invasive delivery[225–227]Infectious DiseasesPathogen targetingCatalytic nanorobotsBacterial clearanceMicePathogen reduction; survival rateTargeted antimicrobial action[222, 228]MusculoskeletalBone regenerationMagnetic nanorobotsBone repairRatsBone formation; structural recoveryRegenerative therapy[211, 214–216]Cartilage repairEnzyme-powered nanorobotsCartilage regenerationRatsCartilage thickness; functional recoveryJoint repair[214, 215] Nanorobotic applications organized by disease type with preclinical models and primary efficacy endpoints Minimally invasive surgery and theranostic applications Nanorobots enable minimally invasive surgery, as small incisions are sufficient to reach anatomical structures that would otherwise require large incisions or rigid instruments. The nanorobots may be directed into the body through the vascular networks, tissue interfaces, or body cavities. TDD, microscale tissue manipulation, or obstruction dissolution can be achieved with either magnetically or acoustically stimulated nanorobots. Such functions could help reduce surgical trauma, shorten recovery time, and improve patient outcomes, particularly in procedures where conventional tools are small or unavailable (Fig. 10e, g) [15, 100, 237, 238]. Advanced nanorobot architectures and multifunctional biomedical interventions. (a) Conceptual design of a multifunctional nanorobot incorporating sensing modules, power sources, data storage, wireless communication, and biomimetic propulsion [246]. (b) Synergistic integration of nanorobots with conventional clinical modalities, including imaging, drug release, surgical assistance, quantification, and cell manipulation [238]. (c) In vivo and ex vivo demonstrations of targeted nanorobot accumulation, magnetic guidance, and imaging-based assessment of therapeutic response [238]. (d) Magnetically actuated nanorobots enabling combined photothermal therapy, fluorescence diagnosis, and photoacoustic imaging under external field control [238]. (e) Nanorobot-assisted microsurgical and interventional procedures, illustrating precise manipulation and controlled interaction with biological tissues [238]. (f) Biohybrid and bacteria-driven nanorobots for targeted therapy, showing magnetic control, pathogen targeting, and cellular damage mechanisms [238]. (g) Clinical-scale demonstration of nanorobot-assisted ocular intervention, highlighting localized targeting and minimally invasive treatment capability [238] Theranostic nanorobots are diagnostic and therapeutic systems integrated into a single platform. Therapeutic nanorobots can also provide real-time localization, biodistribution, and treatment-response feedback by loading imaging contrast agents with therapeutic payloads [239, 240]. This feedback feature enables adaptive interventions by allowing clinicians to modify therapeutic parameters in response to immediate diagnostic data (Fig. 10b, d) [236–238]. Nonetheless, achieving simultaneous reliability in imaging contrast, safe actuation, and control is technically difficult. Further developments in multimodal materials, imaging-guided navigation, and integrated control structures are also needed to realize the full potential of the nanorobotic theranostics in minimally invasive medicine [50, 209]. Cancer therapy and TME modulation Nanorobotic research is a key area of cancer therapy as TMEs are complex and heterogeneous, and not easily accessible. Active penetration of tumor cells by nanorobots through hypoxic or acidic environments, and targeted delivery of therapeutic agents to malignant cells, overcome the main shortcomings of traditional chemotherapy and passive nanomedicine [4, 241]. Similar experimental studies have shown increased intratumoral penetration, local drug delivery, and improved therapeutic efficacy with stimuli-responsive and catalytically powered nanorobots (Fig. 9d, e) [237]. Building on the unified immunomodulatory framework described in Sect. 8.4, nanorobots can regulate both innate and adaptive immune responses within the tumour microenvironment to enhance anti-tumour activity. In addition to drug delivery, nanorobots may also be used to manipulate the tumour microenvironment (e.g., local pH, oxygenation, or immune activity) to sensitize tumors to therapy or inhibit tumor-promoting states. Specifically, nanorobots can modulate tumor-associated macrophages, enhance cytotoxic T-cell responses, and regulate immunosuppressive signaling pathways, thereby overcoming immune evasion mechanisms characteristic of tumor progression. Indicatively, nanorobots capable of in situ immunoactivation or microenvironmental remodeling have performed well in preclinical tumor models (Fig. 9c, f) [237, 242]. Clinical translation still faces numerous challenges, despite promising outcomes. Tumor heterogeneity, interactions with the immune system, and the risk of off-target accumulation require robust safety mechanisms and strict controls. In particular, the complex interplay between tumor cells and the immune system necessitates precise control over immune modulation to avoid unintended systemic immune activation or suppression. A combination of real-time imaging, adaptive control strategies, and fail-safe designs will play an important role in enhancing the nanorobot-based cancer therapies for clinical use [243, 244]. Cardiovascular, neurological, and other interventional applications Beyond oncology, nanorobots have shown great promise in minimally invasive surgery for cardiovascular and neurological diseases, among others. The nanorobots can also be used in cardiovascular medicine to stimulate thrombolysis, scale the vessel surface, or deliver drugs in a controlled manner within blood vessels [25, 54]. They can manoeuvre into small or dark areas that are difficult to reach with traditional catheters, thanks to their small size and active navigation. Nanorobot-based approaches have also been considered to minimize vascular inflammation and optimize tissue repair after ischemic injury (Fig. 10c, f) [55, 238]. When applied to nervous systems, nanorobots enable the delivery of therapeutics to the brain or spinal cord at high spatial resolution, thereby bypassing BBs and minimizing collateral damage. Their capacity to support sensing, imaging, and controlled actuation further renders them particularly useful in applications involving sensitive neural tissues [26, 125]. However, these applications are highly sensitive with respect to safety, precision, and control. It should be rigorously evaluated with respect to long-term effects, clearance, pathways, and interactions with sensitive physiological systems. Preclinical testing and systems-level optimization are therefore paramount for translating nanorobot-based interventional methods into safe and useful clinical therapies (Table 3) [21, 245]. Manufacturing, scalability, and standardization challenges Despite significant advances in BNs and their applications, their practical use is constrained to a great extent by manufacturing, scaling, and standardization. The vast majority of NSs reported to date are built using laboratory-scale protocols designed for demonstration rather than clinical use. Such strategies will be more oriented toward structural innovativeness or functional convergence than toward manufacturability, cost, or regulatory conformity. Addressing this difference requires developing manufacturing approaches that provide tight control over structure and functionality, reproducibility, and scalability, while satisfying regulatory requirements [21]. At the translational level, an early-stage design must be grounded in the fabrication of a nanorobot. The choice of materials and manufacturing routes, along with functional complexity, directly affects scalability, quality management, and long-term reliability. The workflow for the fabrication and design of systems for selected applications is shown in Fig. 11 [21, 243, 247]. Fabrication strategies and scalable biosensing applications of NSs. (a) Overview of major nanorobot fabrication approaches, including microfluidic, electrochemical, physical, and self-assembly methods, highlighting representative process flows and structural control [21]. (b) Nanorobot-enabled biosensing platforms, illustrating microfluidic-assisted immunoassays, magnetic collective self-assembly for viral detection, and aptamer-functionalized microrobots for switchable toxin sensing [235] Fabrication technologies and process control There are various fabrication techniques for nanorobots, including chemical synthesis, molecular self-assembly, template-assisted growth, lithography, and hybrid top-down/bottom-up approaches. The methods enable high precision at the nanoscale in size, shape, surface chemistry, and integration, which are critical to propulsion, targeting, and sensing. Homogeneous nanostructures can be fabricated using microfluidics and electrochemical systems, whereas multifunctional components can be incorporated via physical and self-assembly systems (Fig. 11a) [21, 248]. Even though the processes of such fabrication can be highly versatile, they are highly sensitive to even minor variations in the conditions of the reaction, the purity of the material, or the methods of assembly. This sensitivity can lead to changes in nanorobot structure and operation between batches, thereby impairing reproducibility. Controlling processes is therefore a significant challenge in the manufacture of nanorobots. Other systems under study include automated synthesis systems, microfluidic reactors, and closed-loop process monitoring to reduce operator reliance and improve uniformity. A product design style based on design-manufacturing can significantly enhance product yield, design reliability, and regulatory compliance by eliminating many processing steps and avoiding the use of unstable intermediates in early development [249, 250]. Reproducibility, quality assurance, and scale-up A significant obstacle to clinical translation is also the limited reproducibility of NSs across production batches. Compared with traditional pharmaceuticals or passive nanocarriers, nanorobots are versatile nanocarriers whose functionalities are strongly intertwined by structural, chemical, and dynamic characteristics. Small differences in size distribution, surface functionalization, or the addition of active components can cause this, with strong implications for propulsion efficiency, targeting specificity, sensing resolution, and in vivo behavior [251]. In particular, process-level variations during fabrication can propagate into substantial functional heterogeneity. For example, fluctuations in microfluidic mixing efficiency arising from variations in flow rate ratios, channel geometry, or local hydrodynamic regimes can alter nucleation and growth kinetics, leading to heterogeneity in particle size, morphology, and surface composition. These physicochemical differences directly influence key performance metrics such as propulsion speed, directional stability, and targeting efficiency. Similarly, subtle temperature gradients during self-assembly or material synthesis can significantly affect reaction kinetics, molecular organization, and interfacial energy landscapes. Even small thermal deviations may result in inconsistencies in structural symmetry, catalytic site distribution, or crystallinity, particularly in Janus or hybrid nanorobots. Such asymmetry or uneven catalytic coating can lead to pronounced batch-to-batch variations in propulsion behavior, including reduced speed or loss of directional control. Hence, nanorobots should not be confined to traditional physicochemical characterization; they also require functional performance markers relevant to their intended biomedical applications. Biosensing stability, size, charge, and composition may be necessary, together with propulsion behavior, sensitivity to stimuli, and size. Establishing tight control over microfluidic parameters and thermal conditions, along with real-time process monitoring, will therefore be critical to minimizing variability during scale-up. Another challenge in scaling production from a laboratory to an industrial scale is that processes that are predictable at a small scale are less regular and controllable at a large scale. Continuous manufacturing, modular production structures, and automation are analyzed to identify options for enhancing throughput and consistency. The characterization processes and their performance, especially those with applications in mind, such as biosensing or actuation (Fig. 11b), will be decisive for comparing results of the core measurements across laboratories and for testing regulatory compliance [20, 235]. Cost, robustness, and translational feasibility The clinical application of nanorobotics was later pursued due to its economic and practical benefits. The high cost of production can be attributed to complex fabrication procedures, low productivity, and the need to use specialized or limited raw materials, which make the process inaccessible and non-scalable. From a Good Manufacturing Practice (GMP) perspective, these cost challenges are further amplified for nanorobots incorporating bioactive components such as enzymes, cells, or microorganisms. Such systems require specialized biomanufacturing infrastructure, including controlled cleanroom environments, biosafety-compliant facilities, and aseptic processing lines to ensure sterility and prevent contamination. Achieving sterile, pyrogen-free production is particularly challenging, as conventional sterilization methods (e.g., autoclaving or gamma irradiation) may denature enzymes or compromise biological viability. Consequently, alternative approaches such as sterile filtration, aseptic assembly, or low-temperature sterilization must be employed, increasing process complexity and operational costs. It is important to minimize component redundancy, simplify system architecture, and make systems economically viable by effectively scaling and characterizing materials [252]. In addition, preserving biological activity during large-scale manufacturing requires tight control over environmental conditions, including temperature, pH, and shear stress, as well as stabilization strategies such as encapsulation, cryoprotection, or lyophilization. Failure to maintain these parameters can lead to loss of enzymatic function or cellular viability, thereby reducing therapeutic efficacy and reproducibility. Nanorobots must be structurally and functionally stable during storage, sterilization, transportation, and administration. Minor manufacturing changes or environmental sensitivity put patients at risk and reduce their reliability. Thus, the compatibility of the proposed technology can be enhanced by designing nanorobots in accordance with manufacturing, regulatory, and clinical standards. From a quality control standpoint, GMP-compliant production requires multidimensional release criteria that extend beyond conventional physicochemical characterization. These include assays for enzymatic activity, biological viability (for biohybrid systems), endotoxin levels, and functional performance metrics such as propulsion behavior and targeting efficiency. Ensuring batch-to-batch consistency is particularly challenging, as small variations in biological component integrity can propagate into significant differences in system-level performance. Setting boundaries and making rational decisions are the first steps toward harmonizing the work of academic scientists, industry stakeholders, and regulatory bodies to ensure optimal outcomes. Parallel solutions will be important for the development of NSs for experimental platforms in clinical practice, owing to their cost-effectiveness, durability, expandability, and uniformity [21]. Regulatory, ethical, and clinical translation considerations Not only do technological advancements influence the history and the development of the theoretical experimentation and clinical application of BNs, but also regulatory drivers, ethics, and translational sustainability. Nanorobots can be drug-like, device-like, biological, responsive, semi-autonomous, or any combination of these, and that means that their development and testing cannot be regulated in the standard regulatory platforms. This flexibility escapes approval protocols, safety testing, and post-sales surveillance. Regulatory, ethical, and practical translational considerations must be incorporated from the early design stage to ensure safety, efficacy, and clinical feasibility [6]. Translationally, compliance with regulations and ethical acceptability are not downstream issues but fundamental design considerations. Material choices, actuation, sensing strategies, and control structures can directly influence regulatory classification and risk profile. These factors should be considered early to reduce translation challenges [253]. Regulatory frameworks and approval pathways Currently, no regulatory bodies have established approval channels specifically for NSs: pharmaceuticals, medical devices, biologics, or combination products. Depending on existing regulations governing pharmaceuticals, medical devices, biologics, or combination products, regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others typically screen nanorobots. Classification is typically based on the primary mode of action, which can be difficult to define for multifunctional nanorobots that combine therapeutic delivery, diagnostic imaging, mechanical actuation, and responsive behavior. Such a grey area may make it difficult to review the regulations and create uncertainty about the development schedule and approval process [254, 255]. The regulatory evaluation will be based on extensive preclinical data to demonstrate safety, biodistribution, toxicity, manufacturing reliability, and functional efficacy. In nanorobots, additional criticism may focus on active movement, actuation by external fields, and active or adaptive behavior, which cannot be fully evaluated using conventional assessment criteria. Overall, regulatory issues concern reproducibility of production, quality control, and adherence to GMP standards. Preliminary and ongoing communication with regulatory agencies, the use of standardized testing and reporting processes, and translational risk reduction (Table 4) may help clarify expectations and facilitate approval [6]. Table 4Regulatory, Ethical, and Translational Challenges in NSsDomainKey IssueDescriptionTranslational ImpactMitigation StrategyReferencesCore Translational Bottlenecks (Priority Challenges)Regulatory PathwayProduct classificationNanorobots span drugs, devices, biologicsUnclear approval frameworksEarly regulatory alignment; defined mode-of-action[259–261]Long-term BiosafetyPersistence & accumulationUncertain degradation and clearanceChronic toxicity riskBiodegradable designs; longitudinal studies[262, 263]Manufacturing ConsistencyReproducibilityBatch variability affects functionGMP non-complianceScalable, controlled fabrication[264, 265]Quality AssuranceFunctional consistencyPhysicochemical tests insufficientPerformance variabilityFunctional benchmarking assays[266]System-Level and Clinical Translation ChallengesSafety EvaluationActive behaviorNot captured by standard nanotoxicologyExpanded safety requirementsNew testing frameworks[267, 268]BiodistributionDynamic transportActive motion alters PKUncertain dose predictionImaging-integrated PBPK[269–271]Clinical TrialsEndpoint definitionActive systems complicate outcomesTrial complexityImaging-guided endpoints[270, 272]Control & PredictabilityAutonomy riskLoss of control concernsClinical hesitancyFail-safe mechanisms[273]Infrastructure, Data, and StandardizationData & PrivacyImaging + AIPatient data exposureEthical/regulatory riskSecure data governance[274–276]CybersecurityExternal controlVulnerability to interferenceSafety concernsEncrypted systems[277, 278]StandardizationLack of benchmarksPoor comparabilitySlowed approvalConsensus standards[279, 280]Regulatory ScienceKnowledge gapLimited precedentsReview delaysNanorobot-specific guidance[44, 281]Broader Translational and Societal ConsiderationsPreclinical ModelsTranslational relevanceAnimal–human mismatchClinical failure riskHuman-relevant models[282, 283]Cost & AccessibilityManufacturing expenseHigh production costLimited accessScalable design strategies[284]Interdisciplinary IntegrationFragmentationEngineering–clinical gapInefficient translationIntegrated teams[26, 89, 145]Post-Market SurveillanceLong-term effectsUnknown delayed risksPatient safety concernsExtended monitoring[285, 286]Ethical GovernancePublic acceptanceConcerns over autonomyAdoption barriersPublic engagement[287, 288]Environmental ImpactPost-excretion fateUnknown ecological effectsRegulatory scrutinyEnvironmental assessment[289, 290]Global HarmonizationRegulatory differencesFragmented systemsDelayed deploymentInternational alignment[291] Regulatory, Ethical, and Translational Challenges in NSs Ethical, safety, and societal implications The ethical and social concerns associated with the use of nanorobots in clinical settings extend beyond technical capabilities and legal norms. The potential for nanorobots to move throughout the body, dynamically interact with tissues, and respond to biological or external stimuli raises concerns about patient safety, informed consent, and long-term risk management. Ethical issues of concern include unintended tissue interactions, loss of controllability, off-target effects, and unknown long-term persistence, degradation, or irretrievability. Open reporting of risks, benefits, and uncertainties is required for ethical clinical deployment [256]. Accessibility, equity, and trust will also determine whether the societal aspects of nanorobotic technologies are endorsed. The high cost of development and production could be a constraint, as there would be fears of uneven access to modern therapies. Moreover, combining nanorobots with imaging, sensing, or AI-controlled systems raises additional concerns about data privacy, cybersecurity, and algorithmic accountability. Active ethical evaluation, interdisciplinary communication, and interaction with patients, clinicians, and the general population are essential to being responsible in the innovation process and to developing long-term trustworthiness in society [257]. Current clinical progress and translational barriers To date, most NSs remain in the preclinical phase, with little progress toward clinical trials in humans. At present, fully autonomous nanoscale nanorobots have not yet entered Phase I/II human clinical trials. However, associated technologies, e.g., magnetically directed microdevices, biohybrid micromotors, and novel nanocarrier platforms, offer valuable precedents for translational viability. Among these, externally actuated systems, particularly magnetically guided microdevices and imaging-assisted microrobotic platforms, represent the closest technological pathway to clinical application. Preclinical animal research has demonstrated proof of concept for targeted navigation, controlled delivery, and minimally invasive intervention, and has provided data on safety, performance, and therapeutic use [6]. These emerging platforms are typically based on external-field actuation (e.g., magnetic guidance) combined with real-time imaging modalities, enabling controlled navigation within vascular or luminal environments for indications such as targeted drug delivery, thrombolysis, and localized gastrointestinal or oncological interventions. Although this has been achieved, substantial translational obstacles remain. Despite these advances, several critical barriers continue to limit progression to human trials. These are the lack of a complete explanation of long-term in vivo behavior, the difficulties with large-scale, reproducible manufacturing, and the absence of standardized performance metrics that match those of active, multifunctional systems. Additional challenges include limited real-time control accuracy in complex physiological environments and the absence of clearly defined regulatory pathways for active, adaptive nanosystems. Nanorobotic platforms are also complex, making clinical trial design, endpoint determination, and regulatory assessment more difficult. Consequently, the most feasible near-term translational strategy lies in semi-autonomous or externally controlled NSs with simplified architectures and well-defined actuation mechanisms, which can be more readily aligned with existing clinical workflows and regulatory frameworks. It will take a concerted effort of researchers, clinicians, industry partners, and regulatory agencies to bridge the gap between laboratory innovation and clinical implementation. To accelerate the adoption of safe and effective clinical translation, investment in translational research infrastructure and nanorobot-specific regulatory science would be necessary [258]. Emerging trends and future directions To contextualize recent advances, this section integrates emerging trends in nanorobotics with their comparative positioning relative to established nanomedicine platforms. It outlines the resulting knowledge gaps that must be addressed for clinical translation. The rapid evolution of nanorobotic technology is driving the transition from externally directed, task-oriented systems to intelligent, adaptive, and clinically integrated systems, thereby addressing key limitations of conventional nanomedicine such as passive transport, limited controllability, and suboptimal targeting efficiency. Current trends, including autonomous operation, data-enabled control, and personalized functionality, reflect broader developments in digital medicine, systems biology, and precision healthcare. The goals of these efforts are to strengthen safety and therapeutic effectiveness, and to overcome endemic translational constraints related to controllability, scalability, and incorporation into clinical practice. The schematic summary of the comprehensive design rationality, application environment, and practical trans-theoretical routes of these trends is shown schematically in Fig. 12a-c [22, 292, 293]. System-level design principles, application landscape, and translational outlook of biomedical micro/nanorobots. (a) Multidimensional design framework illustrating the interdependence of function, drive mechanisms, clustering behavior, localization, and manufacturability, and highlighting key physical constraints, such as low Reynolds number and symmetry-breaking effects. (b) Biomedical application ecosystem of micro/nanorobots, spanning biosensing, medical imaging, targeted drug and cell delivery, cancer therapy, and surgery-related operations, and illustrating the progression from laboratory studies toward clinical applications under constraints of controllability, cost, and material degradability. (c) Comparative assessment of major application domains based on potential clinical impact and ease of deployment, together with an innovation–expectation trajectory reflecting translational maturity over time The ongoing development in nanorobotics will be based on materials and fabrication design, as well as on efficient system-level coordination of sensing, actuation, computation, and clinical workflows. The application constraints in real-world clinical needs will be key to achieving practical biomedical impact that meets technological innovation [294]. Autonomous and adaptive NSs A major emerging direction is the development of autonomous and adaptive NSs that operate with minimal external control. A major emerging direction is the development of autonomous and adaptive NSs. The initial nanorobots are programmed to respond to stimuli and to operate continuously. Conversely, next-generation platforms seek to integrate sensing, decision-making, and actuation within a single system to provide context-sensitive responses to evolving BSs. Achieving such autonomy requires efficient integration of multiple functional modules. and symmetry-breaking control at the design level, as illustrated in Fig. 12a [293]. The next example of autonomous nanorobots is that they can detect disease-related biochemical markers, move to the pathological area, deliver treatment, and deactivate or biodegrade upon completion of the task [26]. Adaptive behavior is particularly applicable in heterogeneous and dynamic microenvironments, such as tumors and regenerative tissues, where traditional treatment modalities may fail. Targeting, or release kinetics, propulsion mode specification, or directing propulsion by environmental response would be a significant therapeutic improvement. However, autonomy at the nanoscale is challenging. It is associated with energy efficiency, system complexity, predictability, and safety. Reliable, fail-safe operation must be ensured, as any unintended operation can affect patient outcomes. The use of new directions in smart materials, molecular logic systems, and bio-responsive architectures is likely to permit adaptive nanorobots to balance functionality and controllability [44, 295]. Integration with digital medicine and artificial intelligence The crossroads among nanorobotics, digital medicine, and AI offer promising opportunities to enhance precision, regulation, and personalization. Although most computation occurs at the macroscale, one can integrate AI-powered computation with NSs via imaging, sensing, and external control. With machine learning, navigation planning can be optimized, biodistribution and movement predictions can be made, and therapeutic parameters can be modified in real time, enabling closed-loop intervention. These data-driven integrations have a strong clinical rationale for the use of imaging, targeted delivery, and minimally invasive surgery, as shown in Fig. 12b [293, 296]. Digital health infrastructures can also be used to improve longitudinal monitoring and outcome evaluation. Iterative optimization of nanorobot design and deployment strategies can be informed by imaging, biosensor, and clinical data through analysis. However, such integration can also be associated with problems related to data quality, interpretation, cybersecurity, and regulatory compliance. The perception of AI among clinical professionals will depend on the transparency, robustness, and comprehensibility of AI-assisted control systems. In the future, as digital medicine continues to develop, nanorobotics will likely be central to new diagnostic and therapeutic paradigms [297]. Personalized and precision regenerative therapies Nanorobotics can facilitate targeted, personalized regenerative treatments, potentially informed by patient characteristics and disease states. The absence of the tissue microenvironment, immune responses, and genetic differences is likely to reduce the success of generalized regenerative approaches. Nanorobots may be programmed to respond to each patient’s biochemical, mechanical, or inflammatory signals, enabling high spatial and temporal control of therapeutic agent delivery. These properties are particularly useful in regenerative processes that use stem cells, growth factors, or genes, and dosage and timing are critical to performance [22, 298]. Personalized nanorobotic therapy of the future could integrate patient-derived data (e.g., imaging, biomarkers, genomics) to inform system design, targeting strategies, and treatment plans. Translationally, though, not every application is as feasible to implement. Figure 12c indicates that applications with a delivery or imaging focus will reach maturity earlier than more complex diagnostic or surgical applications, as the comparative analysis of impact and deployment simplicity in Fig. 12c shows. Personalization also entails challenges related to production flexibility, regulatory concessions, and cost efficiency [293]. It will be necessary to develop modular nanorobotics platforms that can be adjusted rapidly while maintaining quality, safety, and regulatory compliance. As these challenges are resolved, nanorobotics will be among the enabling technologies for precision RM and personalized biomedical procedures [84]. Collectively, these emerging capabilities highlight how NSs may overcome the inherent limitations of passive nanomedicine platforms, thereby motivating a direct comparison with existing technologies. Building on these emerging capabilities, it is important to systematically assess how NSs compare with existing nanomedicine platforms, particularly in addressing the limitations outlined above. Such a comparison provides a framework for understanding the unique advantages of active, programmable systems and the extent to which they overcome the constraints of passive nanocarriers. Comparative perspective with existing nanomedicine platforms The contextualization of nanorobots into the wider context of nanomedicine platforms, specifically conventional nanoparticles and microrobots, can be used to gain knowledge of the specific value and constraints of nanorobots. Although the three classes are intended to enhance the accuracy, effectiveness, and safety of biomedical interventions, their sizes, functional complexity, controllability, and translational maturity vary. A comparative method is therefore required to identify clinical cases in which nanorobots confer a clinical advantage, and where more basic or established platforms may be more valuable [10]. Rather than direct substitutes for existing technologies, nanorobots can be considered complementary systems that extend the functional landscape of nanomedicine, particularly in scenarios where active control, adaptability, and deep-tissue interaction are required. In this section, the significant distinctions among platforms are emphasized, and the trade-offs in clinical translation performance are described. Comparison with conventional nanoparticles and microrobots Liposomes, polymeric nanoparticles, and inorganic nanocarriers are among the oldest and best-known nanomedicine platforms. Their key strengths are structural efficiency, scalability, low-cost production, and partially established regulatory frameworks. The main features of these systems are passive transport mechanisms, such as diffusion, increased permeability, and retention effects, as well as surface ligand-based targeting. Consequently, they have registered a significant clinical success in drug delivery, imaging, and vaccine technologies. Clinically approved examples include liposomal drug formulations (e.g., doxorubicin liposomes), superparamagnetic iron oxide nanoparticles for imaging, and polymeric nanocarriers, all of which demonstrate well-characterized pharmacokinetics, safety profiles, and regulatory acceptance. However, their limited motility and responsiveness often result in heterogeneous tissue distribution, inefficient infiltration of dense or poorly perfused tissues, and reduced effectiveness in complex or dynamic disease microenvironments [299, 300]. In comparison, microrobots are larger-scale machines that can employ complex actuation, sensing, and control systems. Microrobots (magnetically or acoustically powered) should enable fine navigation, mechanical control, and local intervention, which is why they are attractive for use in minimally invasive surgery or in the local treatment of accessible anatomical sites. They are, however, relatively large, which limits systemic delivery and access to the microvasculature and interstitial space, and raises concerns about invasiveness, clearance, and long-term safety. Nanorobots are conceptually intermediate between the two platforms. They aim to combine the small size, systemic accessibility, and biocompatibility of nanoparticles with the active functionality and controllability of microrobots. This hybrid solution is proposed as a rationale for its potential applications in RM, targeted therapy, and minimally invasive surgery, where passive delivery is insufficiently effective, and microrobotics is impractical [74]. Advantages, limitations, and performance trade-offs Nanorobots present several unique advantages over current nanomedicine platforms. Guided navigation control and active propulsion enable better localization, increased infiltration into dense tissue, and access to the target microenvironment. Nanorobots are responsive to biochemical or physical signals, programmable, sense their environment, and are conditionally activated to enable precision therapy and adaptive regenerative approaches. Moreover, swarm-based methods can enhance effectiveness, signal-to-noise ratio, and strength in heterogeneous or inaccessible tissues [6]. These advantages, however, come with significant trade-offs. The system is more complex, which makes it difficult to manufacture and deliver quality from a regulatory perspective. Compared with conventional nanoparticles, nanorobots are less translation-ready due to their non-scalable, non-reproducible, and expensive nature, as well as their difficulty in testing long-term biosafety. Importantly, direct head-to-head comparative data between nanorobots and clinically approved nanomedicine products remain limited, reflecting the early-stage development of NSs. Current comparisons are therefore primarily conceptual or based on indirect preclinical evidence rather than systematic clinical validation. In comparison, nanorobots typically trade payload capacity, mechanical strength, and fine manipulation capability for improved biocompatibility and greater systemic delivery potential than microrobots [74]. These distinctions indicate that application-specific requirements should guide platform selection, rather than technological novelty alone, reinforcing the importance of aligning functional capabilities with clinical needs. Traditional nanoparticles remain particularly well suited to high-volume systemic therapies with only modest targeting requirements, whereas microrobots are better suited to localized, mechanically intensive therapies. Nanorobots would be most useful in applications requiring active navigation, environmental responsiveness, and access at small length scales. Future research should focus on establishing standardized benchmarking frameworks and conducting systematic comparative studies, including in vivo evaluations of efficacy, pharmacokinetics, biodistribution, and long-term safety, to enable rigorous clinical validation of NSs relative to established nanomedicine platforms. Each of these trade-offs must be evaluated appropriately to produce a balanced assessment of methods that direct future research toward clinically relevant, realistically translatable nanorobotic applications, as presented in Table 5 [301]. Despite these comparative advantages, the analysis above also reveals several critical limitations that directly give rise to unresolved knowledge gaps, which are discussed in the following section. Table 5Comparative assessment of nanomedicine platforms with respect to functional capabilities, controllability, and translational readinessPlatform TypeTypical Size RangeFunctional ComplexityControllabilityTargeting PrecisionIn vivo Navigation CapabilityManufacturing ScalabilityRegulatory MaturityTranslational Readiness (In vivo validation / GMP precedent / Regulatory engagement)ReferencesLiposomes50–200 nmLowPassiveModerateNoneHighHighTranslational Readiness (In vivo validation / GMP precedent / Regulatory engagement)[302, 303]Polymeric nanoparticles50–300 nmLow–ModeratePassiveModerateNoneHighHighClinical (extensive human use; GMP-established; regulatory precedent)[115, 116]Inorganic nanoparticles10–200 nmLow–ModeratePassiveModerateNoneModerateModerateClinical/late preclinical (advanced in vivo studies; partial GMP precedent; regulatory familiarity)[304, 305]Stimuli-responsive nanoparticles50–300 nmModerateSemi-passiveHighNoneModerateModeratePreclinical (small-animal in vivo studies; limited GMP translation; early regulatory alignment)[100, 306–308]Targeted nanocarriers50–200 nmModerateSemi-passiveHighNoneModerateModerateLate preclinical[277, 309]Synthetic nanorobots10–500 nmHighActiveHighYesLow–ModerateLowPreclinical (primarily small-animal models; no GMP precedent; no formal regulatory engagement)[6, 20]Biohybrid nanorobots100–1000 nmHighSemi-autonomousHighYesLowLowPreclinical (limited in vivo validation; no GMP precedent; regulatory pathway undefined)[113, 114]Enzyme-powered nanomotors50–500 nmModerateAutonomousModerateYesLowLowPreclinical[206, 310]Magnetically actuated nanorobots100–1000 nmHighExternally controlledHighYesModerateLowEarly–mid preclinical (in vivo validation including complex models; emerging GMP considerations; preliminary regulatory alignment)[311, 312]Swarm nanorobots50–500 nmVery highCollective controlHighYesLowLowEarly preclinical (proof-of-concept in vivo studies; no GMP precedent; no regulatory engagement)[313, 314]Soft nanorobots100–1000 nmModerate–HighSemi-activeModerateLimitedLowLowPreclinical[24, 142]DNA origami systems10–100 nmHighProgrammableVery highNoneLowLowIn vitro–early preclinical (limited in vivo validation; no GMP precedent; no regulatory engagement)[315, 316]Cell membrane–coated nanoparticles50–300 nmModeratePassiveHighNoneModerateModeratePreclinical[317, 318]Microrobots1–100 μmVery highHighly controlledVery highYesVery lowVery lowExperimental (limited in vivo validation; no GMP precedent; no regulatory engagement)[319–321]Magnetically guided microrobots10–100 μmVery highExternally controlledVery highYesVery lowVery lowExperimental[322]Bacteria-driven systems500 nm–5 μmHighAutonomousHighYesLowLowPreclinical[323, 324]Sperm-driven micromotors5–50 μmHighSemi-autonomousHighYesVery lowVery lowExperimental[55, 56]Theranostic nanoplatforms50–500 nmHighSemi-passiveHighLimitedModerateModeratePreclinical[181, 325]Hybrid nano–micro systems500 nm–10 μmVery highHybrid controlVery highYesVery lowVery lowExperimental[326, 327]Conventional drug delivery systemsVariableVery lowPassiveLowNoneVery highVery highClinical standard[253, 328, 329] Comparative assessment of nanomedicine platforms with respect to functional capabilities, controllability, and translational readiness Knowledge gaps and research priorities Despite these advancements, several critical knowledge gaps remain, arising directly from the technological and translational limitations identified in the preceding sections. Although biomedical nanorobotics has advanced rapidly, the field remains at an early stage of clinical maturation. Most of the reported systems have demonstrated proof-of-concept functionality, although their applicability to more complex in vivo systems and clinical processes remains poorly established. The solution to these gaps is based on the combined action of engineering, biological knowledge, and translational strategy. Clarifying and ranking unresolved obstacles helps guide future research and yields clinically significant results in RM and MIIs. Technical and engineering challenges The ability to integrate multiple functions propulsion, sensing, targeting, control, and payload delivery remains a major engineering challenge, as highlighted by the complexity performance trade-offs discussed above. Current nanorobots can perform only a single task simultaneously, yet achieving an efficient, multifunctional, and robust system remains difficult due to size, onboard power, and material mismatches. Nanoscale generation and energy delivery in vivo are exit nodes, especially for autonomous or adaptive systems that must be actuated independently [330, 331]. Similarly, the limited control, robustness, and predictability of nanorobots in complex biological environments reflect the constraints of active navigation identified in earlier sections. Directed motion can be disrupted by stochastic forces, heterogeneous fluid dynamics, biological impediments, and dynamically varying tissue properties, thereby impairing performance. Most available computational models and simulations simplify real-world situations; therefore, they cannot forecast real-world behavior. Moreover, NSs are not readily comparable with prior work due to the lack of standardized metrics for assessing propulsion efficiency, navigation accuracy, responsiveness, and task accomplishment. To address these problems, nanoscale fabrication, system-level modeling, closed-loop control measures, and the design of generally acceptable performance measures will have to vary [93]. Biological and translational knowledge gaps One of the greatest impediments to clinical implementation, as identified in the comparative analysis, is the persistence of biological uncertainties. Although much is known about short-term biodistribution and acute toxicity, little is known about the long-term behavior of active, potentially autonomous nanorobots in vivo. The knowledge gap identified here is narrow, encompassing chronic immune responses, immune memory after repeated administration, long-term tissue interactions, and possible interference with normal physiological processes. The latter are of great importance, especially in regenerative applications that may require nanorobots to be maintained, to interact dynamically with tissues, and to operate over longer timescales [332]. In addition, the limitations of existing preclinical models further exacerbate translational gaps identified in the comparative framework. The most commonly used animal models are not representative of human tissue structure, immune complexity, or pathophysiology, thereby reducing the predictive value of preclinical data. In addition, active, intelligent nanosystems have not been used in regulatory science, making it difficult to establish approval criteria, safety standards, and acceptable performance standards. Long-term in vivo experiments, more disease-relevant models, and greater focus on regulatory concerns in initial studies and system engineering will help overcome these biological and translational gaps. Strategic directions for future research Future research should therefore prioritize strategies that directly address the engineering, biological, and translational limitations outlined above, with an emphasis on functional robustness, safety, reproducibility, and clinical viability. Design strategies emphasizing modularity, simplicity, and scalability will be essential to reduce system complexity while maintaining functionality. The realization of smart, bioreactive materials, low-power actuation schemes, and molecular- and material-level control systems will likely emerge as interest in ensuring robust and adaptive nanorobotic behavior grows [21]. In addition, practical translational constraints must be explicitly addressed. These include: (1) Improving storage stability through material optimization and stabilization strategies (e.g., encapsulation, lyophilization), (2) Developing GMP-compatible sterile manufacturing workflows, and (3) Reducing production costs via scalable fabrication and simplified system architectures. From a clinical translation perspective, a stepwise roadmap is required to place greater emphasis on longitudinal studies that examine the long-term safety, immune interactions, degradation pathways, and functional outcomes in model diseases of interest. NSs, when integrated with allied fields such as systems biology, digital medicine, and artificial intelligence, may be used for predictive modeling, improved control approaches, and the optimization of individualized therapy regimens. Lastly, to automate the process, the organization would need to make significant investments in enabling translational research platforms, standardized appraisal frameworks, and interdisciplinary collaboration among engineers, biologists, clinicians, and regulatory scientists. In this way, the field will be positioned to advance the rationalization of safe, effective, and clinically significant nanorobotic technologies [294]. Addressing these interconnected challenges will be essential for translating emerging nanorobotic innovations into clinically viable systems, thereby bridging the gap between technological potential and real-world application. Conclusions Nanorobotics has emerged as a promising paradigm for developing minimally invasive biomedical solutions, surpassing passive nanomedicine and traditional technologies. The ability of nanorobots to autonomously interact with BSs, be environmentally responsive, and be programmable at the nanoscale offers unexplored opportunities to engage BSs accurately. There have been major strides in material design, fabrication, propulsion, targeting, and intelligent control structures, providing a firm basis for applications in RM and minimally invasive therapy, as discussed in this paper. Regenerative Nanorobots are deployed in regenerative environments to maintain or supply dynamic bioactive signals, stem cell instructions, and immune regulation, with high spatial and temporal accuracy, in response to changing tissue microenvironments. Their capacity to deliver drugs to tumors with high precision, infiltrate tumors, serve as part of theranostics, and access anatomically restricted locations in the body suggests they can be significantly less invasive than conventional techniques and offer more specific therapy for disease in interventional medicine. It can be noted that advances in imaging and real-time tracking have enabled feedback-controlled and adaptive nanorobotic activity in vivo and in silico, and experimental systems are now moving closer to clinical applications. Despite these developments, major challenges remain. Translational barriers, such as BBs, regulatory uncertainty, and long-term biosafety and manufacturing reproducibility, are limiting translational progress. The complexity of active, multifunctional nanosystems demands new evaluation systems that integrate biological functionality, dynamic behavior, and system-level safety. Moreover, implementing the latter at scale, at low cost, and in clinically realistic scenarios remains a significant challenge. Looking ahead, the trajectory of biomedical nanorobotics is likely to favor translationally feasible systems over maximal functional sophistication. In particular, modular design strategies based on biodegradable and biocompatible materials, standardized performance metrics, and early regulatory alignment will be essential to accelerate clinical adoption. From a translational standpoint, the most plausible pathway for clinical implementation within the next 5–10 years is expected to involve externally controlled, imaging-guided systems particularly magnetically actuated micro/nanorobotic devices for assistive and interventional applications rather than fully autonomous, self-navigating nanorobots. Although digital medicine and artificial intelligence are increasingly integrated into NSs, the current emphasis on fully autonomous AI-driven decision-making may be overestimated, given ongoing limitations in real-time control, interpretability, and regulatory acceptance. Conversely, long-term biosafety including material persistence, degradation pathways, and chronic biological interactions remains comparatively underestimated, despite its central importance for clinical translation and regulatory approval. Nanorobotics can be proposed as a paradigm shift in biomedical technology, given its cross-disciplinary perspective and emphasis on translational biomedical research. Realizing this potential will require sustained, interdisciplinary efforts to balance innovation with safety, scalability, and regulatory readiness. Acknowledgements Not applicable. Abbreviations Biomedical nanorobots Regenerative medicine Nanorobotic systems Minimally invasive interventions Biological systems Blood-brain barrier Physiologically based pharmacokinetic Good Manufacturing Practice Food and Drug Administration European Medicines Agency Artificial intelligence Tumor microenvironments Positron emission tomography Chemical Vapor Deposition Single-photon emission computed tomograph Targeted drug delivery Biological Barriers Modular design framework Near-Infrared Extracellular matrix Superparamagnetic Iron Oxide Nanoparticles Author contributions Na Liu **,** Shi Tang: Conceptualization, Methodology, Writing – original draft; Writing – review & editing.Yang Song **,** Shasha Yu: Data curation, Formal analysis; Writing – review & editing.Haishan Zhang **,** Yizi Wang: Supervision, Writing – review & editing.All authors reviewed and approved the final manuscript. Funding Not applicable. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not application. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Na Liu, Shi Tang and Shasha Yu contributed equally to this work. Contributor Information Yang Song, Email: songy18@sj-hospital.org. Haishan Zhang, Email: zhanghaishan99@sohu.com. Yizi Wang, Email: wangyz3@sj-hospital.org. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.